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ABSTRACT
REGULATION O F GLUCOSE-6-PHOSPHATE DEHYDROGENASE BY
POLYUNSATURATED FATTY ACIDS IN CULTURED RAT HE PATOCYTES
Laura P. Stabile
The goal of this research is to understand the molecular mechanism(s) by which
polyunsaturated fatty acids inhibit gene expression of the lipogenic enzymes.  The model
enzyme that we are using to study this phenomenon is liver glucose-6-phosphate
dehydrogenase (G6PD).  In order to determine if regulation of G6PD occurred at a
transcriptional or a posttranscriptional step in rat hepatocytes, enzyme activity, mRNA
accumulation and transcriptional activity of the G6PD gene were measured in the
presence and absence of a polyunsaturated fatty acid, arachidonic acid.  Insulin and
glucose stimulated a 5- to 7-fold increase in G6PD activity and mRNA.  This increase
was attenuated by 60% due to the addition of arachidonic acid to the medium of primary
rat hepatocytes in culture.  Transcriptional activity of the G6PD gene was measured using
nuclear run-on assays.  The changes in mRNA accumulation occurred in the absence of
changes in transcription.  To more precisely define the regulated step, the abundance of
G6PD mRNA both in the nucleus and in total RNA was measured using a ribonuclease
protection assay with probes designed to cross intron-exon boundaries.  Amounts of
precursor mRNAs for G6PD in the nucleus changed in parallel with the amount of mature
mRNA.  The decrease in pre-mRNA accumulation was only caused by long chain
polyunsaturated fatty acids not monounsaturated fatty acids.  Further, this decrease was
not due to toxicity of the cells as a result of fatty acid oxidation.  Thus, regulation occurs
at a nuclear posttranscriptional step and represents a novel form of regulation by fatty
acids.  Our hypothesis is that regulation of G6PD occurs very early in the processing
pathway through the interaction of a trans-acting factor with a cis-acting element within
the precursor mRNA for the gene.  Using transient transfection analysis of a mouse G6PD
cDNA construct in rat hepatocytes, a putative fatty acid response element has been
localized within 2.3 kb of the G6PD mature sequences.  Identification of the pathway
involved in the inhibition of de novo fatty acid synthesis by polyunsaturated fat will help
understand the molecular basis for diseases associated with the consumption of fat, such
as diabetes, obesity and atherosclerotic disease.
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CHAPTER 1.  LITERATURE REVIEW
Introduction
Atherosclerotic heart disease is a major cause of illness and death in the United
States.  For many years, the American public has been encouraged to decrease their
consumption of dietary fat to less than 30% of their daily caloric intake and to increase to
2:1 the ratio of polyunsaturated to saturated fatty acids in their diet.  These health
recommendations have been based solely on correlation between increased risk of
atherosclerotic disease, level of circulating serum lipids and consumption of dietary fat.
The molecular basis for these dietary health recommendations is not known.
Fatty acids play important roles in cell structure and cellular metabolism.  They
are components of phospholipids which provide structural support to cell membranes.  In
addition, they are involved in various intracellular signaling pathways including
activation of Ca2+-dependent protein kinase (1), growth factor signaling (2) and G-protein
signaling (3).  Polyunsaturated fatty acids are also the precursors to the prostaglandins,
thromboxanes, and leukotrienes which are potent intracellular mediators that control a
variety of complex processes such as inflammatory response, regulation of blood
pressure, and induction of blood clotting.  Another very important role is that fats, in the
form of triacylglycerols, are a highly efficient form of metabolic energy storage in
adipocytes.  This is because fats are less oxidized than either carbohydrates or proteins
and thus yield significantly more energy upon oxidation.  Fat can be obtained from a
variety of sources including de novo synthesis, diet and release from adipose tissue stores.
The addition of polyunsaturated fat to a high-carbohydrate diet has been shown to
decrease the expression of many of the lipogenic genes (4).  Lipogenesis is defined as the
conversion of carbon from glucose or amino acids to triacylglycerol (Fig. 1).  The
reactions of glycolysis, the citric acid cycle and fatty acid synthesis give rise to the carbon
backbone of the fatty acids and glycerol.  The reactions that generate NADPH provide
hydrogen atoms for the fatty acids.  Members of the family of fatty acid biosynthetic
enzymes include malic enzyme, glucose-6-phosphate dehydrogenase (G6PD), acetyl-CoA
carboxylase (ACC), ATP-citrate lyase and fatty acid synthase (FAS).  We are interested in
elucidating the mechanism(s) by which polyunsaturated fatty acids inhibit the expression
of the genes for the lipogenic enzymes; that is, how dietary fat decreases the d  novo
production of fat in the body.  The model enzyme that we are using to study this
phenomenon is liver G6PD.  G6PD catalyzes the first step in the pentose phosphate
pathway, producing ribose sugars necessary for nucleotide biosynthesis and reducing
2
Figure 1.  Schematic outline of fat biosynthesis.  G6PD, glucose-6-phosphate
dehydrogenase;  6PGD, 6-phosphogluconate dehydrogenase;  CL, ATP-citrate lyase;
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equivalents in the form of NADPH (Fig. 2).  In addition to fatty acid biosynthesis, the
reducing equivalents are used for other biosynthetic reductive reactions such as the
regeneration of glutathione by acting as a hydrogen donor for glutathione reductase.  The
later function of NADPH ensures the integrity of erythrocyte membranes by protection
from oxidative damage.  Thus, G6PD has several major physiological roles consisting of
lipogenesis in the liver and adipose tissue, synthesis of nucleic acids for growing cells,
and protection from oxidative stress.  The liver is our target organ since this is the major
organ that makes fatty acids and then secretes them into the bloodstream packaged in
lipoprotein particles.
The discovery that fatty acids can affect lipogenic gene expression and thus
modulate a cell’s metabolic state is essential in understanding responses to dietary
changes.  Identification of the pathway involved in the inhibition of de novo fatty acid
synthesis by dietary polyunsaturated fatty acids (PUFA) will help understand the
molecular basis for diseases associated with consumption of fat, such as diabetes, obesity
and atherosclerotic disease.  This may give insight into new diet recommendations or
drug intervention as well as understanding novel mechanisms of gene regulation.  The
goal of my research is to characterize a cell culture model which mimics the regulation of
G6PD observed in the intact animal and to use this model to identify cis-acting sequences
within the G6PD precursor mRNA (pre-mRNA) which may be responsible for mediating
the inhibition by fatty acids.
Regulation of G6PD by hormonal and nutritional factors
The members of the lipogenic family of enzymes are coordinately regulated by a
variety of nutritional and hormonal factors (5).  Carbohydrate and polyunsaturated fats are
the two primary nutritional factors that act to either stimulate or inhibit lipogenic enzyme
activity, respectively.  Hormonal factors which alter lipogenic enzyme activity include
insulin, thyroid hormone (T3), glucocorticoids and glucagon.  Insulin, T3 and
glucocorticoids are positive regulators whereas glucagon is a negative regulator of
lipogenic activity.  First, I will discuss the hormonal effectors followed by a discussion of
the nutritional factors in both the intact animal and in cells in culture specifically for
G6PD.
Hormonal factors
Like other lipogenic enzymes, G6PD activity in the livers of starved rats is low
and increases when rats are fed a high-carbohydrate, fat-free diet (6-8).  This starvation-
4
Figure 2.  Physiological role of the glucose-6-phosphate dehydrogenase (G6PD) reaction.
G6PD catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconolactone with
the concomitant production of NADPH from NADP+.  6-phosphogluconolactone is an
intermediate of the pentose phosphate pathway.  NADPH is the coenzyme used for many












refeeding paradigm is commonly used to increase hepatic lipogenesis and results in a
dramatic increase, or “overshoot”, in the activity of the lipogenic enzymes followed by a
decrease in activity to a new steady-state amount (9,10).  The diet-induced changes seem
to be dependent on the levels of circulating insulin and glucocorticoids, and the level of
carbohydrates in the diet.  These conclusions were based upon endocrine gland
ablation/replacement therapy experiments.  Rats that were either adrenalectomized or
treated with streptozotocin which destroys the pancreatic -cells thereby stopping insulin
production failed to induce G6PD activity upon refeeding (11).  However, when the rats
were treated with glucocorticoids or insulin replacement therapy, respectively, G6PD
activity increased above control samples.
The positive regulatory effect of insulin and glucocorticoids observed in the intact
animal has also been observed in primary rat hepatocytes.  Primary culture systems
provide a chemically-defined environment to allow the examination of a combination of
hormonal and nutritional regulators of enzymatic and metabolic activities.  Several
investigators have used this approach to study the role of insulin and glucocorticoids on
the expression of G6PD.  Kurtz and Wells (12) were the first to show that insulin induced
G6PD activity in primary rat hepatocytes.  Others have since confirmed this effect (8,13-
15). Glucocorticoids have also been shown to be positive regulators of G6PD in both the
intact animal and in the primary culture system.  Glucocorticoids and insulin by
themselves stimulate G6PD mRNA levels (16).  When both are present at the same time,
the levels increase in an additive manner.  The molecular mechanism causing the change
in RNA levels has not been determined.
Glucagon and T3 also alter G6PD activity, although the results are confounded
due to discrepancies between results obtained in the intact animal versus those obtained
in cell culture experiments.  Injecting a rat with glucagon, the hormone most associated
with the starved state, has been shown to decrease G6PD activity (6).  In contrast,
injecting a rat with T3 has been shown to increase G6PD activity (17).  However, neither
glucagon nor cAMP decrease G6PD activity in cultured rat hepatocytes.  In addition, T3
does not increase G6PD activity in cultured cells (8).  Thus in the intact animal, glucagon
and T3 may be changing the accumulation of another metabolite or cellular factor which
is not present in cultured hepatocytes.
Nutritional factors
In rats that have been fasted and then refed a high-carbohydrate, fat-free diet,
G6PD activity has been shown to increase approximately 16-fold, reaching the highest
value after the rats were on the diet for 48 to 72 h (18).  While part of this response may
6
be due to changes in insulin concentrations in the blood, the type of carbohydrate in the
diet is also important.  Diets with fructose as the carbohydrate source result in greater
increases in the rates of fatty acid synthesis and the increases in the activities of the
lipogenic enzymes than when glucose is the primary carbohydrate source (19).  In
addition, fructose increases G6PD activity independently of hormonal stimuli.  In this
regard, the refeeding induced increase in G6PD activity can be maintained in diabetic rats
by feeding fructose (19).  The increase in activity in whole animals due to carbohydrate in
the diet is related to an increase in enzyme synthesis and a decrease in degradation rates
(20-22).
The role of carbohydrates in regulating G6PD activity in primary rat hepatocytes
is not clear due to discrepancies in the increase due to glucose among various
investigators.  Some studies have shown an effect of monosaccharides such as glucose on
enzyme activity (14) while others have not (12,23).  These differences may be due to
varying contents of gluconeogenic amino acids present in the media used in these studies.
In this respect, an intermediary metabolite of glucose or fructose is thought to activate
glucose responsive genes (24-27).  Therefore, variations in the content of gluconeogenic
amino acids in the different tissue culture media could cause the accumulation of this
putative metabolite, regardless of the addition of exogenous glucose.
In contrast to the stimulatory effect of carbohydrates, polyunsaturated fat inhibits
G6PD activity.  Several lines of evidence indicate that the inhibition by dietary fat is
specifically due to PUFA in the diet (28).  First, when the carbohydrate intake of each rat
is held constant and fat is added in addition, the activity of the lipogenic enzymes is
inhibited in the rats receiving the fat (29).  Second, saturated and monounsaturated fats do
not inhibit G6PD activity (29).  In rats that were fed a high-carbohydrate, fat-free diet
supplemented with palmitate (16:0), stearate (18:0) or oleate (18:1) G6PD activity was
not inhibited whereas dietary supplementation with linoleate (18:2) and linolenate (18:3)
did result in a decrease in G6PD activity.  Third, the inhibition has been shown to be
independent of essential fatty acid status.  Rats deficient in essential fatty acids have
increased rates of lipogenesis and these rates are decreased when essential fatty acids are
given (28).  However, the addition of more PUFA to a diet already adequate in essential
fatty acids further inhibits activity.  Finally, the inhibition is not a result of a change in the
protein to calorie ratio of the diet (30).  In rats, supplementation of the diet with 20%
additional energy as safflower oil inhibits the activity of G6PD better than
supplementation of the diet with 20% additional energy as beef tallow, a saturated source
of fat.
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The decrease in G6PD activity by PUFA in the intact animal has also been shown
in primary rat hepatocytes (14); primary mouse hepatocytes are unresponsive to this
treatment (31).  The effects of PUFA in primary rat hepatocytes have been shown to be
specific to polyunsaturated fats, not monounsaturated or saturated fats.  In addition, the
decrease in G6PD activity is not due to a generalized toxicity of the cells due to lipid
oxidation as assessed by measurement of thiobarbituric acid-reactive substances in the
medium (32) and ATP concentrations (14).  It has been hypothesized that eicosanoids
may be the metabolite of fatty acids that is responsible for mediating the inhibition.
However, use of specific inhibitors to block arachidonic acid and linoleic acid
metabolism does not consistently block the inhibition of lipogenic enzymes by PUFA
(7,33,34).  A second hypothesis is that PUFA action is via activation of peroxisome
proliferator activated receptors (PPARs) which then bind along with their heterodimeric
partner, retinoid X receptor, to peroxisome proliferator responsive elements.  PPARs are
members of the steroid-like receptor superfamily and are located in the nucleus of a
number of tissues, including liver and adipocytes.  This also has led to inconsistent results
based on recent in vivo and in vitro studies.  First the PUFA response elements that have
been identified do not contain a PPAR response element nor do they bind PPAR (35,36).
Second saturated, monounsaturated and polyunsaturated fats all have equal potency as
activators of PPAR to induce PPAR-mediated gene transcription (37,38).  Thus, they do
not exhibit the selectivity of regulation to explain PUFA control of gene expression.  A
third hypothesis is that PUFA may interfere with other hormone action, such as insulin
action, by modifying membrane lipid composition thereby altering hormone release and
signaling.  Some evidence supports this hypothesis (35,39) but other studies do not (40)
which suggests that such a PUFA-insulin interaction may not be universal.  A final
hypothesis is that the effect is direct through a PUFA-specific mechanism.  In support of
this hypothesis, several PUFA response elements have been identified (40,41) which are
distinct from the insulin response elements in the same genes.  It may be unlikely that any
one mechanism can fully account for the nuclear actions of PUFA.
Structural characterization of the G6PD gene
The mouse G6PD gene is 18 kb long and contains 13 exons.  The second intron
makes up almost half of the gene (Fig. 3).  The G6PD gene is an X-linked gene which
undergoes transcriptional silencing in one of the 2 alleles resulting in expression of only a
single copy of the gene per cell.  Its promoter is embedded in a CpG island which is
conserved from mice to humans (42).  G6PD has a promoter with two GC-boxes and a
non-canonical TATA box, TTAAAT, but no CAAT element.  These GC-boxes are
8
Figure 3.  Structure of the G6PD gene.  The G6PD gene is 18 kb in length and contains
13 exons.  The transcription start site is indicated with an arrow.  Exons 1 and 2 are
represented by a narrow solid box.  Exons 3-13 are represented by a shaded box.  Intron 2
comprises almost half of the gene structure.  Restriction sites are listed on the top line:  B,
BamHI;  H, HindIII;  E, EcoRI.
Structure of the G6PD gene
EBH
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essential for the expression of transiently expressed constructs in HeLA and HepG2 cells.
The transcription factors Sp-1 and AP-2 have been shown to bind to the GC-boxes (43).
The rat, human and mouse transcriptional start sites have all been mapped.  The primary
start site in mouse (44) is located 3 bases downstream of that used in human (45) and rat
(46).  The reason for these slight differences is most likely due to experimental variation
and probably does not represent the presence of two separate start sites.  The translational
start codon is located in exon 2.  The number of exons, locations of the introns in the
coding sequence and the size and sequence of the exons are conserved between species.
However, exon 13 has been found to contain many sequence differences between species.
In contrast, intron size and sequence are not conserved (47,48).  The 3’-UTR is
approximately 600 bp in length and contains a single poly(A) site (L. P. Stabile and L. M.
Salati, unpublished).
Tissue specificity of G6PD regulation
G6PD is essential to all tissues to provide the ribose sugars for nucleotide
biosynthesis and NADPH for reductive biosynthetic reactions.  Because of its
biochemical role and because it is found in all organisms analyzed thus far, G6PD is
regarded as a typical housekeeping gene.  Regulation by the various hormonal and
nutritional factors discussed previously occurs primarily in the liver and adipose tissue
(49).  The amount of G6PD activity varies between tissues (50) as well as the amount of
G6PD mRNA (44).  For example, kidney contains 2 times the amount of activity found in
cardiac muscle (50) and 2.6 times the amount of mRNA (44).  In addition, Corcoran et al.
(51) generated transgenic mice expressing 20 kb of the human G6PD gene which
included 2.5 kb of 5’-flanking DNA and 2 kb of downstream sequences and found a
similar pattern of tissue-specific distribution and level of expression of the transgene as
the endogenous gene.  Therefore, the tissue-specific expression of G6PD is
pretranslational.
For some genes, tissue-specific regulation is achieved via alternate promoter
usage between tissues, such as with the glucokinase (52) and acetyl-CoA carboxylase (53)
genes.  Hodge t al. (44) has shown by S1 nuclease analysis and primer extension
analysis of G6PD mRNA that the same transcriptional start site is used in liver, kidney
and adipose tissue, thus this gene has a single promoter.  Therefore, the tissue-specific
regulation is not a consequence of alternate promoter usage.  A second possibility is that
there are differences in the composition of the basal transcriptional machinery between
tissues.  Nuclease hypersensitive sites are often regions of the DNA that interact with
transcription factors, such as with the S14 gene where different hypersensitive sites
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correlate with differential tissue-specific expression (54) and changes in expression
during development (55).  A nuclease hypersensitivity analysis of the 5’-end of the gene
revealed three hypersensitive sites (HS):  HS1, HS2, and HS3 (44).  To measure
expression in different tissues, the amount of nuclear pre-mRNA for G6PD was
measured.  The abundance of G6PD pre-mRNA was 3- to 4-fold higher in liver than in
heart or kidney and was associated with the disappearance of HS3 in the heart and kidney.
These results are consistent with tissue-specific regulation being regulated at a
transcriptional level, but this has not been demonstrated directly.  HS1 and HS2 may be
required for basal expression of the gene whereas HS3 may be involved in the tissue-
specific regulation.  Further analysis of these hypersensitive regions is necessary to fully
understand the mechanisms behind the tissue-specific differences in the amount of G6PD
expression and differences in regulation.  The mechanisms by which various tissues
differentially express G6PD activity most likely will vary with each cell type and with the
functional requirement for NADPH in the cell.
G6PD expression is also regulated in mammary glands.  G6PD expression is
increased in lactating mammary tissue versus non-lactating controls, presumably due to
an increased need for the lipid component of milk (56).  G6PD is also regulated by
nutritional factors in this tissue.  For example, dietary carbohydrate has been shown to
stimulate G6PD activity in this tissue (57).
Oxidative stress is another important regulator of G6PD.  This type of regulation
occurs primarily in the lung and liver (58,59).  G6PD activity increases in addition to
various other antioxidant enzymes when rat alveolar type II cells are exposed to
hyperoxic conditions, suggesting a direct correlation between increased G6PD activity
and increased oxidative stress (58).  In primary rat hepatocytes, ethanol increases G6PD
activity, which may be a consequence of an induction of oxidative stress (59).  This
increased activity is due to increased G6PD protein synthesis and mRNA accumulation.
Signaling is thought to occur through the metabolism of ethanol to acetaldehyde.  Free
radicals are then generated through the metabolism of acetaldehyde by acetaldehyde
oxidase.  In support of this idea, the addition of acetaldehyde to primary rat hepatocytes
increases G6PD activity and mRNA but has no effect on lipid biosynthesis (60).  In
addition, Pandolfi et al. (61) has shown by targeted disruption of the G6PD gene that
G6PD is essential to protect cells against even mild oxidative stress.
G6PD activity has also been reported to be stimulated by cell growth (61).  In this
regard, G6PD activity is increased with the addition of epidermal growth factor (EGF) to
primary rat hepatocytes (62).  This effect appeared to be disconnected from lipogenesis
since EGF repressed both the induction of malic enzyme and the insulin stimulated
11
incorporation of acetate into triglycerides.  EGF was shown to increase the relative rate of
synthesis of G6PD and the mRNA accumulation.  This growth effect may not be tissue-
specific since tumor cells from various tissues have been reported to have increased
G6PD activity (63).  The increase in G6PD activity due to cellular growth may reflect an
adaptation to an increased need for nucleic acids and NADPH.
Mechanisms of G6PD regulation
Expression of a gene can be controlled at many levels including transcription of
the DNA into the primary transcript, processing of the primary transcript into the mature
message, transport of the mature message into the cytoplasm, mRNA stability, translation
of the message into a protein and posttranslational events such as protein stability and
modification.  Regulation at each of these steps can be very complex and can involve
many accessory factors.  The majority of studies to date have focused on transcriptional
control mechanisms, but the importance of posttranscriptional mechanisms in regulating
gene expression is becoming increasingly clear.
The exact regulatory step involved in the regulation of G6PD by nutritional and
hormonal factors is still not entirely known.  The nutritionally- and hormonally-induced
changes in G6PD enzyme activity are accompanied by comparable changes in the
concentration of the G6PD protein not changes in catalytic efficiency of the enzyme.  To
determine if the total amount of G6PD protein was altered in response to dietary factors,
antibodies against G6PD were used in immunoprecipitation experiments on liver
supernatants from rats that were either fed a high-carbohydrate diet (64,65) or a high-fat
diet (66).  In both cases, changes in G6PD enzyme activity paralleled changes in the
amount of the enzyme.  Glucagon has also been shown to regulate G6PD enzyme activity
by decreasing G6PD concentration (6).  Thus, both increases and decreases in activity can
be accounted for by changes in the amount of G6PD protein.
Changes in the concentration of the protein can be due to changes in the rate of
protein synthesis or changes in the rate of protein degradation.  The relative rate of G6PD
synthesis was measured by incubating hepatocytes with 3H-leucine followed by
immunoprecipitation of G6PD with a specific antiserum (67).  The amount of
radiolabeled G6PD was compared to 3H-leucine incorporated into total protein to
calculate the relative rate of synthesis of the enzyme.  In another study, Winberry and
Holten (68) measured the amount of 125I-anti-G6PD bound to liver polysomes.  The
amount of 125I-anti-G6PD bound to the polysomes under saturating conditions directly
correlates with the rate of synthesis of the protein.  The results from both of these
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experiments demonstrated that the changes in activity and amount of the enzyme could be
accounted for by changes in the rate of synthesis of G6PD.
The changes in the rate of synthesis can be caused by changes in translational
efficiency of the mRNA or by changes in mRNA abundance.  To distinguish between
these possibilities, an i vitro rabbit reticulocyte translation system was used to measure
mRNA abundance (17).  All of the changes observed in the rate of G6PD synthesis were
accounted for by changes in the amount of mRNA.  This was the first report to suggest
that regulation of G6PD occurred at a pretranslational step.  Following the isolation of
G6PD genomic and cDNA clones, further work was done to corroborate these findings.
Using a rat liver G6PD cDNA to measure mRNA levels in response to refeeding a high-
carbohydrate diet, G6PD mRNA levels increased 13-fold, accounting for the changes
observed in enzyme activity (69).
Changes in mRNA accumulation can be due to changes in transcription or to
changes in posttrancriptional regulatory processes, such as mRNA stability or processing.
To test if the transcriptional activity of the gene was regulated in response to a high-
carbohydrate diet or a diet containing PUFA, nuclear run-on assays were performed.  Our
laboratory has shown that regulation of G6PD by both dietary carbohydrate and dietary
fat occurs exclusively at a posttranscriptional step in mice (15).  Multiple controls were
used to verify that the absence of transcriptional regulation was real (15).  The G6PD
probes did not contain repetitive elements, the probes were authentic G6PD sequences
(both cDNA and genomic probes), and the transcription signals reflected hybridization to
only the transcribed strand of the G6PD gene.  Transcription was measured at multiple
positions along the gene so as to exclude elongation of transcription as a regulated step.
In addition, both positive and negative controls were included (i.e. fatty acid synthase,
stearoyl-CoA desaturase, and phosphoenolpyruvate carboxykinase) and they all exhibited
the expected transcriptional changes.
In order to determine more specifically the step involved in this
posttranscriptional regulatory mechanism, Hodge and Salati (70) used ribonuclease
protection assays to measure the amount of pre-mRNA in the nucleus after feeding mice a
high-fat diet.  An 80% decrease in G6PD mRNA in total cellular RNA was accompanied
by an 80% decrease in nuclear pre-mRNA.  Regulation of pre-mRNA in the nucleus
could result from a change in the rate of processing of the pre-mRNA, stability of pre-
mRNA or mature mRNA in the nucleus, or a block in transport of mRNA from the
nucleus to the cytoplasm.  Further characterization of the regulation of G6PD indicates
that transport of the mRNA from the nucleus to the cytoplasm is not regulated.  In this
regard, the rate of accumulation of G6PD pre-mRNA in the nucleus paralleled the rate of
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accumulation of mature mRNA in the cytoplasm and changes in the nucleus preceded
changes in cytoplasmic accumulation.  In addition, splicing of the primary transcript and
changes in the rate of stability did not appear to be regulated.  Deadenylation of mRNA is
also known to be involved in normal turnover (71).  However, selective disappearance of
the 3’-most portion of the pre-mRNA with dietary treatment was not observed, suggesting
that this mechanism is unlikely.  Thus, regulation of the amount of G6PD pre-mRNA
probably occurs in the nucleus very soon after transcription of the primary transcript.
Regulation of pre-mRNA accumulation by PUFA has not been previously described and
thus represents a novel mechanism for control of gene expression by dietary fat.  Further
identification of the cis-acting elements and trans-acting factors involved in regulation of
this gene are currently underway.
Regulation of lipogenic/glycolytic enzymes by nutrients and hormones
Dietary manipulation results in coordinated changes in the concentrations of
several lipogenic enzymes, suggesting common regulatory mechanisms.  In each case the
primary mechanism involves changes in mRNA abundance.  Most of the observed
changes are due to changes in transcription although more and more examples of
posttranscriptional mechanisms have been reported.  Cis-acting DNA sequences have
been identified in many of these genes using cell culture and transfection techniques as
well as the factors that bind to these sequences.  Each enzyme is discussed separately
because there are both similarities and differences in the mechanisms by which they are
regulated.
Acetyl-CoA carboxylase
Acetyl-CoA carboxylase catalyzes the first committed step and key regulatory step
in fatty acid synthesis which is the conversion of acetyl-CoA to malonyl-CoA.  Malonyl-
CoA is the substrate used by fatty acid synthase as the 2 carbon source in each round of
fatty acid synthesis.  ACC exists in 2 isozymic forms that are attributed to transcription
from two separate genes, ACC- and ACC- (72,73).  In rats, ACC- gives rise to a 265
kDa isozyme which is expressed in all cell types; however, its activity is the greatest in
liver, adipose tissue and lactating mammary gland.  ACC- gives rise to a 275-280 kDa
isozyme which is mainly expressed in the skeletal and heart muscle and is thought to
function in the regulation of fatty acid -oxidation in the mitochondria (73-75).  These
two isoforms of ACC control the amount of fatty acids in the cell.  Expression of the
ACC- form is regulated by diet and hormonal factors and thus will be the only one
discussed.
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ACC- is regulated by both short- and long-term regulatory mechanisms.  Short-
term regulation involves allosteric interactions by citrate and long-chain acyl-CoAs,
phosphorylation and dephosphorylation, and changes in the size of the enzyme.  The
enzyme exists in two different states, an inactive protomer consisting of two monomeric
subunits, and an active polymer.  The active polymer forms a filamentous structure that is
made up of many protomers which is subject to short-term regulation by the factors
mentioned above.  Long-term regulatory mechanisms include regulation by nutritional
and hormonal factors.  ACC is increased by insulin, dexamethasone and dietary
carbohydrate.  Conversely, fatty acids inhibit the hormonal induction (76).
Transcription of the rodent ACC- gene is initiated from two promoters, promoter
I (PI) and promoter II (PII), which are located 12 kb apart (77,78).  The first four exons
are alternatively spliced to form a heterogeneous population of mRNAs differing in their
5’-UTRs.  These mRNAs encode the same protein product because exon 5, which
contains the start codon for translation, is present in all ACC- transcripts.  Alternative
promoter usage and splicing are two of the mechanisms by which the expression of ACC
is regulated.  Alternative promoter usage is involved in tissue-specific expression of the
mRNA in response to starvation-refeeding.  When rats are fed a standard chow diet,
expression of ACC is primarily due to transcriptional initiation at PI in epididymal fat
tissue.  Starvation followed by refeeding a fat-free diet greatly stimulates transcriptional
activity at the ACC PI in this tissue.  This is followed by a large increase in ACC mRNA
accumulation (79).  PII is not active under these conditions.  In liver, both promoters are
active in response to feeding.  When rats are fed a standard chow diet, low basal
transcription activity is only seen from PII.  Refeeding a purified fat-free diet after 72 h of
starvation causes increased transcriptional initiation from both promoters with activity at
PI being higher (80).  In the chick, nutritional changes of ACC, which also may have
multiple promoters, are mediated by changes in the rate of transcription of the gene (81).
Regulation of ACC by polyunsaturated fat has been studied in both primary rat
hepatocytes and primary chick embryo hepatocytes.  Incubation of rat hepatocytes in
media containing palmitate (16:0), oleate (18:1), linoleate (18:2), arachidonate (20:4) or
docosahexanoate (22:6) resulted in a 30-35% decrease in the hormonal induction of ACC
(76).  This inhibition was the same with all chain lengths and degrees of unsaturation.  In
chick hepatocytes, palmitate (16:0), hexanoate (6:0), octanoate (8:0), oleate (18:1), and
arachidonate (20:4) all decreased activity.  However, only the medium-chain fatty acids
(6:0 or 8:0) and arachidonic acid inhibited transcription of the gene suggesting that a
metabolite of hexanoate or octanoate, possibly 6 or 8 carbon acyl-CoA, plays a role in this
effect (82).
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PI and PII in the rat have very different structures.  PI contains TATA and CAAT
boxes, 2 fatty acyl-CoA elements and a dinucleotide repeat repressor element (83,84).
The repressor element may be responsible for the low level of expression of PI under
normal conditions in the liver.  PII contains multiple Sp-1 sites, an AP-2 site, a glucose
response element, and a tumor necrosis factor response element (85).  Both contain
insulin response elements (80).  The physiological significance of this tissue-specific
promoter usage and transcript diversity is unclear at this time.  It has been hypothesized
that there is a physical and metabolic compartmentalization of ACC molecules which is
related to the increasingly diverse functions of fatty acids in physiological processes such
as the specialization of adipocytes for fat storage and the synthesis of fatty acids for
incorporation into cell membranes.  In support of this hypothesis, Barber et al. (86) have
demonstrated the existence of a third promoter, PIII, in the ACC- gene that results in
tissue-specific expression of a novel ACC mRNA isoform which is 259 kDa.  Thus, ACC
is very complex and the mechanisms involved in regulation of this gene will most likely
prove to be very complicated.
ATP-citrate lyase
Acetyl-CoA is generated in mitochondria by pyruvate dehydrogenase or by the
oxidation of fatty acids.  When the need for ATP synthesis is low such that oxidation of
acetyl-CoA via the citric acid cycle and oxidative phosphorylation is also low, this
mitochondrial acetyl-CoA may be stored as fat.  A problem arises because fat
biosynthesis occurs in the cytosol but the mitochondrial membrane is impermeable to
acetyl-CoA.  To solve this problem, acetyl-CoA enters the cytosol in the form of citrate.
ATP-citrate lyase catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and
CoA with the concomitant hydrolysis of ATP to ADP and phosphate.  The product of this
reaction, acetyl-CoA, is important in several biosynthetic pathways, including lipogenesis
and cholesterogenesis.  Thus, ATP-citrate lyase is a member of the lipogenic family of
enzymes.  Starvation, feeding a high-carbohydrate diet, feeding a high-fat diet, insulin
and glucagon all regulate the amount of ATP-citrate lyase in liver and adipose tissue.
Gene expression of ATP-citrate lyase is increased in the livers of rats fed a fat-
free, high-carbohydrate diet and decreased in the livers of rats that have been starved (13).
In contrast, ATP-citrate lyase expression is decreased in the livers of rats fed a diet high
in polyunsaturated fat.  These changes in gene expression are accompanied by
comparable changes in the rate of transcription of the gene.  Another study suggests that
regulation by starvation and refeeding occurs by both transcriptional and
posttranscriptional mechanisms (87).  In this regard, in rats that have been starved and
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then refed a high-carbohydrate diet, transcriptional activity of the gene increased to a
maximum of 24-fold at 12 h.  Transcriptional activity continued through 48 h with a 17-
fold increase over starved animals.  Conversely, ATP-citrate lyase mRNA levels
increased after 6 h of refeeding, peaked at 12 h and then decreased to low levels by 48 h.
This suggests that changes in the transcriptional activity of the ATP-citrate lyase gene
account for the early responses to refeeding but that decreased stability of the message
predominates as the control mechanism at later times.
Regulatory sequences have been identified in primary rat hepatocytes using
transient transfection of plasmids containing the 5’-flanking region of the rat ATP-citrate
lyase gene fused to the chloramphenicol acetyltransferase gene (CAT).  The region from
-104 to -20 of the ATP-citrate lyase gene was shown to be responsible for regulation due
to insulin and PUFAs.  The region from -61 to -49 was shown to have sequence similarity
to the insulin-responsive regions of fatty acid synthase and acetyl-CoA carboxylase genes
(88).  Unfortunately, these analyses were done only with minimal regions of the ATP-
citrate lyase promoter.  The limits of the flanking DNA used in the transfection studies
were not established using techniques such as DNase I hypersensitivity.  DNase I
hypersensitive sites often correlate with regions of regulatory significance thus this type
of experiment would give an indication if there were more regulatory sequences upstream
of the region that was tested.  Thus, in the absence of corroboration by others these results
are very preliminary.
Fatty acid synthase
Fatty acid synthase plays a central role in de novo lipogenesis in mammals,
catalyzing all reaction steps in the conversion of acetyl-CoA and malonyl-CoA into
palmitate.  The production of palmitate involves a series of seven enzymatic reactions for
each 2 carbon addition, until the final 16 carbon product is produced.  In animals, this
enzyme is the product of a single gene and is a 500 kDa multifunctional enzyme because
all seven enzymatic activities are located on a single peptide.  Regulation of FAS by
nutritional factors, such as carbohydrate and PUFA, have been shown to occur primarily
at the level of transcription, although some posttranscriptional components have been
reported (40,89-91).
In birds, mice, and rats, mRNA amounts and transcription rate of fatty acid
synthase are low in the livers of starved animals and increase with refeeding (89,92-94).
Changes in the rate of fatty acid synthase gene transcription can account for most of the
changes in mRNA accumulation and enzyme activity (89,92,93,95).  The increase in
expression due to refeeding can be blocked by injection of cAMP or glucagon (94).  In
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addition, in both rats and mice, the activity and mRNA abundance of FAS is low in livers
of diabetic animals and increases 10-fold or more with insulin treatment (94-97).  In
parallel, FAS transcription is low in the livers of diabetic mice and insulin increases the
mRNA abundance and transcription of FAS by 19- and 7-fold, respectively (94).  In rat
hepatocytes, insulin increases the activity and mRNA accumulation for FAS (13,98).  The
effect of insulin on mRNA accumulation is dose-dependent and the induction by insulin
requires glucose.  In HepG2 cells, a human hepatoma cell line, glucose alone increases
the accumulation of FAS mRNA 2.7- to 5.4-fold (91,99).  This effect of glucose is
accompanied by an increase in stability of fatty acid synthase mRNA but not a change in
the transcriptional activity of the gene.  The half-life for FAS mRNA was 30 h in the
presence of glucose and 4.4 h in the absence of glucose.  Whether or not the insulin
response is direct or indirect remains a controversial issue.
In chickens, T3 and not insulin is the primary inducer of FAS gene expression by
increasing the rate of transcription of the gene (100,101).  Neither cAMP nor glucagon
cause a decrease in the transcription rate of the gene, even though the transcriptional rate
is inhibited by starvation in birds (89).  The addition of glucagon or dibutyryl cyclic AMP
to insulin and T3 stimulated chick hepatocytes results in a 70-80% decrease in FAS
activity, a 60% decrease in mRNA abundance, and no effect on transcriptional activity of
the gene.  The mechanism of this posttranscriptional regulation by glucagon and cAMP
has not been elucidated.
Regulation of FAS by PUFA has been studied in both the intact animal and in
cells in culture.  This occurs primarily at the transcriptional level.  Regulation of FAS by
fatty acids is dependent on the length and the amount of desaturation of the fatty acids.
Suppression of FAS requires that the fatty acid contain at least 18 carbons and 2 double
bonds (103).  In rats fed menhaden oil (20:5/22:6), hepatic FAS mRNA decreased 80%
whereas the transcription rate was reduced by 94% (40,103).  Thus, alterations in
transcription account for all of the regulation of FAS by PUFA.
The molecular mechanisms by which FAS is positively regulated by glucose and
insulin has been studied.  A glucose response element and an insulin response element
have been localized to +283 to +303 and -71 to -51, respectively (104,105).  The
upstream stimulatory factor, USF, family of transcription factors have been shown to bind
to both sites (106,107).  Recently, a novel factor has been reported to bind to the insulin
response element, not the glucose response element, but the identity of this protein has
not yet been made (108).  The molecular mechanisms of FAS regulation by PUFA has not
yet been elucidated.  One possible trans-acting factor which has been implicated in PUFA
mechanism is sterol regulatory element binding protein (SREBP).  This protein belongs to
18
a novel family of membrane-bound transcription factors that regulate multiple enzymes
required for cholesterol and fatty acid synthesis.  SREBPs directly activate FAS
expression along with several other genes involved in fatty acid synthesis (109).
However, the exact role of SREBP in PUFA regulation remains to be demonstrated.
Malic enzyme
Malic enzyme catalyzes the conversion of malate to pyruvate with the production
of NADPH from NADP+.  Malic enzyme provides a source of NADPH for fatty acid
synthesis in addition to the enzymes of the pentose phosphate pathway, G6PD and 6-
phosphogluconate dehydrogenase.  The contributions of NADPH from malic enzyme and
from the pentose phosphate pathway are variable in different species.  For example, in
birds, the pentose phosphate pathway is less active thus malic enzyme provides most of
the NADPH needed for fatty acid synthesis in the liver (110).  In contrast, in the rodent
liver and adipose tissue, there is an equal contribution from these two different pathways
(111,112).
Regulation of malic enzyme by thyroid hormone has been studied extensively.
Treatment of euthyroid rats with T3 has been shown to stimulate hepatic malic enzyme
mRNA accumulation 10- to 15-fold, whereas transcriptional activity increased only 3- to
4-fold with this treatment (113,114).  This suggests that at least some component of the
increase is due to posttranscriptional regulation.  This posttranscriptional regulation was
shown to occur in the nucleus since the accumulation of malic enzyme nuclear pre-
mRNA increased 10- to 15-fold in response to T3.  The increase of nuclear pre-mRNA
paralleled the increase seen in malic enzyme mRNA in the cytoplasm (115).  Thus
regulation of malic enzyme by T3 is due to both changes in the transcriptional activity of
the gene as well as by regulation of nuclear stability.
In rodent and avian liver, the activity, amount and rate of synthesis of malic
enzyme is low during periods of starvation.  Refeeding starved animals a high-
carbohydrate, low-fat diet results in a 20- to 30-fold increase in the synthesis of malic
enzyme (116-118).  The contributions of transcriptional versus posttranscriptional
processes to the accumulation of malic enzyme mRNA varies between species and with
various treatments.  For example, in birds and chick embryo hepatocytes, regulation of
malic enzyme is mediated by changes in transcription of the gene (119).  In contrast, in
rodents, regulation of malic enzyme occurs by both transcriptional and posttranscriptional
processes (120).  When euthyroid rats are fed a high-carbohydrate diet, malic enzyme
mRNA accumulation increases 7- to 8-fold.  Transcriptional activity of the gene and
nuclear RNA concentration do not increase which suggests that changes in stability of the
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cytoplasmic message are responsible for the regulation of malic enzyme gene expression.
Additional evidence for posttranscriptional regulation was observed in mice where
changes in mRNA accumulation for malic enzyme due to starvation and refeeding were
greater than the changes in the transcriptional activity of the gene (121).
Both saturated and unsaturated fatty acids have been shown to regulate malic
enzyme expression at a pretranslational step.  Medium chain saturated fatty acids,
hexanoate (6:0) and octanoate (8:0) inhibit the T3-induced increases in malic enzyme
gene transcription in chick embryo hepatocytes (122).  However, longer chain fatty acids
do not have this inhibitory effect.  PUFA have been shown to regulate malic enzyme
expression both in the intact animal and in cells in culture.  Feeding meal trained rats a
high-carbohydrate diet supplemented with 10% menhaden oil (20:5/22:6) decreases malic
enzyme mRNA accumulation (5).  Similar results were obtained in cultured rat
hepatocytes.  Addition of linoleic acid (18:2) or arachidonic acid (20:4) inhibits the
stimulation of dexamethasone, insulin and glucose (13).  Further elucidation of this
pretranslational mechanism has not been described.
One study demonstrated evidence for posttranscriptional regulation by fat.
Increases in the carbohydrate to fat ratio in the diet increases the amount of cytoplasmic
RNA 7- to 8-fold in the absence of changes in transcription or nuclear mRNA
accumulation (115). The mechanisms of posttranscriptional regulation of malic enzyme
by PUFA have not yet been elucidated.
Spot 14
Spot 14 (S14) is a small (17 kDa) acidic protein with no similarity to other known
mammalian gene products.  Although the specific function of the protein is not yet clear,
the responses of this mRNA to a number of stimuli are similar to those of the lipogenic
enzymes (123).  The protein has been localized to the nucleus suggesting that it may act
as a transcription factor (124).  Recently, Moncur et al. (125) has reported the localization
of the human S14 gene to the long arm of chromosome 11 (11q13.5).  The S14 gene is
specifically expressed in tissues that produce lipids for use as metabolic fuel such as
lactating mammary, white and brown adipose tissue, and liver (126).  In liver, its
expression is increased by thyroid hormone, glucose and insulin.  Conversely, S14
expression is inhibited by glucagon and PUFA.
S14 mRNA accumulation changes rapidly in response to stimuli that modulate
fatty acid formation.  S14 protein levels have been shown to parallel those of its mRNA.
Induction of S14 mRNA by carbohydrate feeding results from an increase in the rate of
gene transcription (127).  This has been mimicked in cultured hepatocytes by keeping the
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insulin level constant and altering the glucose level.  Insulin is necessary for the
carbohydrate response but it does not appear to be a direct effector.  Using transient
transfection to define sequences mediating carbohydrate regulation, a 30 bp segment
(-1457 to -1428) in the 5’-flanking region of the gene has been shown to be essential for
the glucose response (128).  In addition, 5’-deletions in other parts of the S14 gene led to
significant loss of carbohydrate response.  Therefore, there must be other elements in the
5’-flanking region that influence the response to glucose and interact with this identified
response element (129,130).  Multiple trans-acting proteins have been found to be
important in this regulation although there is still conflicting evidence as to the identity of
these factors.  Comparison of the L-pyruvate kinase and S14 carbohydrate regulatory
regions revealed a sequence with 9 out of 10 bp identity, suggesting that a common
nuclear factor is involved the regulation of both of these genes (128).
Insulin has been shown to increase hepatic S14 mRNA levels in streptozotocin-
induced diabetic rats (131,132).  Less than half of this induction could be accounted for
by an increase in transcription, thus insulin regulates S14 by both transcriptional and
posttranscriptional mechanisms.  In this regard, insulin increases the ratio of mature to
precursor S14 mRNA which is due to an increase in splicing efficiency of S14 pre-
mRNA, suggesting a role for insulin in the processing of lipogenic genes (133).  This
posttranscriptional mechanism has also been observed with dietary sucrose (134).
The increases in S14 by glucose is synergistically enhanced by T3.  In this regard,
injection of T3 into hypothyroid rats increases S14 mRNA levels 15- to 20-fold.  When
these rats are starved overnight and then treated with T3, little change is observed in S14
mRNA levels (135).  Three distinct T3 response elements are found between -2718 and -
2558 of the 5’-flanking region (136).  The mechanism for the synergism with the
carbohydrate response element has not been determined.
Regulation of S14 gene expression by PUFA in both adult and weaning rats
occurs by inhibition of S14 gene transcription.  For example, feeding rats a high-
carbohydrate diet supplemented with menhaden oil (20:5/22:6) inhibited S14 mRNA
accumulation and gene transcription by 50% (40).  Using S14-CAT chimeric fusion
constructs and transient transfection in primary rat hepatocytes, a cis-acting region for
PUFA control has been localized to -220 to -80 bp (39).  This region is distinct from
either the carbohydrate or T3 response element of the gene.  A trans-acting PUFA-




Stearoyl-CoA desaturase catalyzes the 9-cis desaturation of long chain fatty
acids. The preferred substrates are palmitoyl (16:0)- and stearoyl (18:0)-CoA which are
converted to palmitoleoyl (16:1)- and oleoyl (18:1)-CoA, respectively.  Palmitoleic and
oleic acids are the major constituents of membrane phospholipids and triacylglycerol
stores in adipocytes.  The ratio of stearic acid to oleic acid is an important factor which
influences cell membrane fluidity.  Alteration of this ratio may play a role in aging and
several diseases such as cancer, diabetes, obesity, hypertension and neurological and heart
diseases.
Two genes encode stearoyl-CoA desaturase activity, SCD1 and SCD2 (137,138).
Cloned DNAs encoding both SCD1 and SCD2 have been isolated and characterized from
both rat and mouse.  The tissue-specific expression of these two genes is quite different.
Under normal conditions, mouse and rat SCD1 mRNAs are expressed constitutively in
adipose tissue but not in liver (138,139).  The expression is induced in liver upon feeding
a fat-free, high-carbohydrate diet, and to a lesser extent in the kidney, lung, spleen, and
heart.  SCD1 mRNA is also negatively regulated in the liver by supplementing a high-
carbohydrate diet with PUFA (140).  Conversely, SCD2 is expressed constitutively in the
brain and induced in the kidney, lung, spleen and adipose tissue in response to a high-
carbohydrate diet.  SCD2 is not expressed in liver under either condition (139,141).  The
mechanisms responsible for the differences in the tissue-specific expression and dietary
induction of expression of each of these genes have not been elucidated.
SCD is regulated by the same nutritional and hormonal factors as other lipogenic
enzymes.  Hepatic SCD1 levels in rats and mice are increased 40-fold by refeeding a fat-
free, high-carbohydrate diet to starved animals (142).  Insulin, T3, estradiol and
dexamethasone all have been shown to stimulate the activity of SCD in both animal and
cell culture studies (98,143-146).  Changes in hepatic SCD expression are due to changes
in the transcriptional activity of the gene (140).  Recently, Waters et al. (147) have
localized a T3 response region to a 70 bp sequence in the SCD1 promoter.  In addition,
they have demonstrated specific binding of nuclear protein from mouse liver nuclear
extract to a 43 bp sequence.  Response elements for the other stimulatory factors have not
been identified.
Regulation of SCD by PUFA has been well characterized in mouse liver
(140,148), primary hepatocytes (149), rat adipose tissue (150) and 3T3-L1 adipocytes
(151).  Mouse liver SCD1 mRNA was decreased 95% by PUFA accompanied by a 75%
decrease in transcription.  Waters t al. (41) localized a PUFA response region to a 60 bp
fragment in the SCD1 5’-flanking region in HepG2 cells which shows specific binding to
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nuclear proteins.  A homologous region in the SCD2 promoter also mediates PUFA
specific repression in transfection experiments.  This suggests that there may be a
common transcriptional mechanism in both liver and adipose tissue for the inhibition by
PUFA.  The inhibition by PUFA has been shown to be insulin-independent (148).  In
support of this result, an insulin response region has been mapped to a region distinct
from the PUFA response region.  Further characterization of the nuclear factor(s)
involved in the PUFA response has not been reported.  This PUFA response region has
no sequence similarity to the other identified PUFA response elements.
The effect of PUFA was also examined on the expression of the SCD1 gene in
mature adipocytes.  In contrast to the results obtained in liver tissue, PUFAs regulated the
expression of the adipocyte SCD1 gene by regulating stability of mRNA transcripts.
Treatment of 3T3-L1 adipocytes with arachidonic acid decreased SCD1 enzyme activity
and mRNA accumulation (151).  However, arachidonic acid did not alter the transcription
of the gene whereas the half-life of the SCD1 mRNA was reduced form 25.1 h to 8.5 h.
The interpretation of these results in view of the similar PUFA response element in SCD1
and SCD2 has not been reconciled.
Pyruvate kinase
Pyruvate kinase is a rate-controlling glycolytic enzyme which catalyzes the
formation of pyruvate and ATP from phosphoenolpyruvate and ADP.  It also is a control
point in regulating flux of glucose to fatty acids.  There are 2 genes for pyruvate kinase,
PK-L and PK-M for the liver and muscle types, respectively.  PK-L encodes 2
isoenzymes, R- and L-types, by alternate promoter usage (152,153).  The term “L-PK
gene” refers to the gene for the L-type isoenzyme in the PK-L gene and this gene is
regulated by dietary and hormonal control.
Hepatic L-PK activity (154) and mRNA expression (155,156) are decreased as a
result of starvation or diabetes and are increased with a high-carbohydrate diet or insulin
administration, respectively, to diabetic rats.  Glucagon inhibits the accumulation of
hepatic L-PK mRNA and the increase in transcription by insulin via cAMP through both
pre- and post-translational mechanisms (157,158).  cAMP increases the phosphorylation
of L-PK by protein kinase A to decrease enzyme activity (159) whereas insulin increases
L-PK activity by stimulating dephosphorylation of L-PK (160).  The increase in mRNA
due to glucose or insulin is due to an increase in gene transcription in rats (157,161).  In
hepatocytes, glucose and insulin have been shown to increase L-PK gene transcription
and also to increase the stability of mRNA (158).  The reasons for the differences in
transcriptional versus posttranscriptional mechanisms in these two systems is unclear.
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L-PK activity and mRNA are decreased by 60 and 70%, respectively, in the livers
of rats by the addition of PUFA to a high-carbohydrate diet (5,35,162).  This effect has
been shown to be specific to PUFA since oleic acid (18:1) does not elicit this response.
In addition, PUFAs decrease the increases in enzyme activity, mRNA levels and
transcriptional activity of L-PK by insulin and glucose in primary rat hepatocytes in
culture (35).
In order to further characterize the regulation of L-PK, both positive and negative
cis-acting regulatory elements have been identified in the rat L-PK promoter using CAT
reporter assays in cultured cells or transgenic approaches.  Three positive regulatory
regions were identified which are designated L-I (-94 to -76), L-II (-149 to -126), and L-
III (- 170 to -150) (163,164).  Both the L-II and L-III elements are required for stimulation
of L-PK gene transcription by carbohydrates as well as for cell-type specific expression
(165,166).  The LIII element itself possesses responsiveness to carbohydrate whereas the
LII element acts as an accessory element in this regulation.  As noted earlier, comparison
of the segments of the 5’-flanking regions of the S14 and L-PK genes conferring the
glucose response shows a region with 9 out of 10 identity (128).  Hepatocyte nuclear
factor 4 (HNF-4) and proteins of the nuclear factor-1 (NF-1) family have been shown to
bind to LII.  The LIII element binding protein is still unclear because there is conflicting
evidence for the binding proteins involved (163,167,168).
Transient transfection of L-PK-CAT fusion constructs in primary cultured
hepatocytes demonstrates that the PUFA response element is on the L-II element (35).
Examination of the PUFA responsive regions in S14 and L-PK genes revealed a region
with 80% sequence identity.  PPAR has been reported to be involved in PUFA regulation
of L-PK gene expression, as it was suggested for other lipogenic enzymes.  In support of
PPAR as a mediator in this response, the retinoid X receptor-PPAR heterodimer is able to
recognize HNF-4 binding sequence which is found in LII (the location of the PUFA
response element) (169).  One piece of evidence against PPAR is that PUFA-mediated
repression of L-PK gene expression is observed in PPAR deficient mice (170).  Thus, the
mechanism of PUFA mediated regulation for this gene is still unclear.  HNF-4 has been
speculated to be involved because recently fatty acyl-CoA thioesters have been shown to
be ligands of HNF-4 in the human apolipoprotein CIII gene promoter (171).  Thus, long
chain fatty acids may modulate the transcriptional activity of HNF-4 by binding as their
acyl-CoA thioesters to the ligand binding domain of HNF-4.  This in turn may alter the
affinity of HNF-4 for its cognate promoter element.  In this manner, fatty acids may
indirectly alter the expression of HNF-4 controlled genes.
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Summary
 Enzymes involved in de novo fatty acid biosynthesis are coordinately regulated
by a variety of hormonal and nutritional factors; however, this regulation is achieved
through a variety of mechanisms within a liver cell with examples of both transcriptional
and posttranscriptional mechanisms.  Transcriptional regulation of lipogenic enzymes has
been better characterized than the posttranscriptional control mechanisms.  G6PD is
unique in that regulation by dietary carbohydrate and PUFA is mediated exclusively at a
posttranscriptional level in the nucleus.
The reasons for the exclusive regulation of G6PD by a posttranscriptional
mechanism while other lipogenic enzymes are primarily regulated by transcriptional
mechanisms (or a combination of both) is unclear.  One possible reason for
posttranscriptional regulation is that G6PD participates in many aspects of intracellular
metabolism, not just lipogenesis, whereas other lipogenic enzymes are more exclusive to
this pathway.  A posttranscriptional mechanism might permit increased expression of
G6PD in liver when the needs for lipogenesis are great but maintain uniform expression
in all cells for its roles in cellular detoxification and nucleotide biosynthesis.  Even
though G6PD does not use the intracellular pathway related to transcriptional regulation
by diet, the mechanisms involved in posttranscriptional regulation of G6PD by diet may
be common to all lipogenic enzymes.  The additional posttranscriptional regulation of
genes controlled by transcriptional mechanisms would permit more rapid changes in the
expression of these genes in response to changes in nutritional status.  G6PD provides an
ideal model to study this regulation because of the absence of transcriptional regulation
which would otherwise confound the interpretation of such experiments.
Posttranscriptional regulatory mechanisms
Posttranscriptional regulation can occur at many stages during the processing of a
primary transcript through its translation in the cytoplasm.  Regulation can occur in the
nucleus or in the cytoplasm.  Nuclear regulation can involve capping, polyadenylation,
splicing, nonsense-mediated decay, nuclear pre-mRNA stability, or regulated processing.
There are many cis-acting elements within a transcript which may be involved in
regulating a message at the posttranscriptional level.  The trans-acting factors which
interact with these sequences have been identified in some cases.  Some elements are
relevant for all mRNAs whereas others are unique to individual transcripts.  Gene
regulation is a very complex process and there are many examples of genes that are
regulated at each of these steps.  I will discuss at least one example of regulation at the
major points in posttranscriptional control.
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Capping
The 5’ cap structure on mRNA plays multiple roles in gene expression and its
regulation.  It enhances splicing, RNA stabilization and translation.  Most nuclear
functions of the cap are mediated through protein factors which recognize the cap
structure.  A nuclear cap binding complex has been described which specifically
recognizes the cap structure (172).  Immunodepletion of this nuclear cap binding complex
from nuclear splicing extracts efficiently inhibited splicing of an adenovirus mRNA
(173).  Further analysis revealed that an early step of the spliceosome assembly was
inhibited by the lack of this protein complex.  In yeast, the cap affects stability of certain
messages via a deadenylation dependent-decay mechanism (174,175) which means that
the poly(A) tail must be shortened to an oligo(A) tail before removal of the cap.  Once
decapping has occurred, the transcript is then exonucleolytically degraded by specific 5’
to 3’ nucleases.  A specific decapping enzyme along with a 5’ to 3’ exonuclease, XRN1,
has been identified in yeast (176,177).  Disruption of the XRN1 gene results in
accumulation of deadenylated transcripts lacking caps (178).  Mammalian mRNAs
without caps have been shown to be 4-fold less stable than their capped counterparts (71).
A similar decay mechanism may be involved in mammalian cells since a 5’ to 3’
exonuclease has also been discovered in mammals (179).  Finally, the cap is important in
efficient translational activity (180).  In translation, the cap is recognized by the cap
binding protein, eIF-4E, which is part of a multi-protein complex (eIF-4F) required for
translational initiation.
Splicing
Alternative splicing of pre-mRNAs is the most common way that splicing
functions to regulate gene expression.  This is a powerful and versatile regulatory
mechanism that can affect the quantitative control of gene expression as well as the
functional diversification of proteins.  It can involve skipping or including a particular
exon, choosing a single exon or multiple exons from a series, or alternative use of
adjacent 5’ or 3’ splice sites.  Alternative splicing is regulatory in a wide spectrum of
processes.  For example, the expression and function of a large number of genes involved
in programmed cell death are regulated by alternative splicing, including death receptors
and intracellular components of the death machinery (181).  Alternative splicing also
affects neuronal processes such as the ability of neurons to communicate electrical and
chemical signals and to develop synaptic connections (182).  In addition, a wide range of
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alternative splicing examples are found in genes involved in developmental processes
(183).
The most well characterized example of alternative splicing is for sex
determination in Drosophila.  In Drosophila, the default sex is male.  Female-specific
expression of the sex lethal (Sxl) gene and the transformer (tra) gene results in repression
of the male state and expression of female-specific genes through a cascade of regulated
splicing events that dictate sexual identity (184).  Sxl acts at the top of the cascade to
regulate the splicing of tra RNA as well as its own transcripts.  The male Sxl mRNA
encodes a truncated, nonfunctional protein due to the inclusion of a male-specific exon
with a stop codon.  This exon is skipped in females and results in the production of a
functional RNA-binding protein (185).  This process is regulated by the Sxl protein itself
which binds to a U-rich sequence both upstream and downstream of the male-specific
exon thus preventing recognition of this exon by the splicing machinery (186,187).  The
roles of alternative splicing of the other genes involved in this cascade have also been
identified using genetic and biochemical approaches (188,189).  Some factors which
regulate this process include constitutive splicing factors, such as serine-arginine (SR)
rich proteins, as well as RNA secondary structure and steric constraints.
The metabolism of the spliced introns has also been suggested to be critical for
regulation of gene expression.  For example, the rate of intron turnover may influence the
levels of nucleotide available for further rounds of transcription or it may affect the
availability of splicing factors and other posttranscriptional events.  Clement et al. (190)
recently reported the first calculated half-life for an intron from a higher eukaryotic cell,
an intron from the constant region of the mouse T-cell receptor- gene.  Using a
tetracycline-regulated promoter, the spliced intron and its pre-mRNA had half-lives of 6.0
 1.4 min and 3.7  1.0 min, respectively.  Analysis of the function of spliced introns in
nuclear metabolism will most likely lead to novel mechanisms involved in the regulation
of gene expression.
Poly(A) tail
The poly(A) tail found at the 3’ end of most mRNAs has been implicated as an
early step in the degradation of many mRNAs (191) and also is important in the
developmental regulation of mRNA translation (192).  Transfected mRNAs which lack a
poly(A) tail and mRNAs synthesized in culture with 3’-deoxyadenosine have been shown
to be degraded more rapidly than their adenylated counterparts (193,194).  In eukaryotes,
most, if not all, of the functions of the poly(A) tail are mediated via its association with
the multifunctional poly(A) binding protein.  Depletion of this protein results in rapid
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degradation of the mRNA (193).  The exact mechanism for how poly(A) tail removal
enhances degradation is still unclear.  It is thought that following deadenylation,
degradation of the body of the transcript occurs by removal of the 5’ methyl cap and
subsequent 5’ to 3’ exonucleolytic digestion of the mRNA (174).  A variation of this
pathway has also been demonstrated to occur in which transcripts undergo 3’ to 5’
exonucleolytic decay subsequent to poly(A) tail shortening (195).  Several cis-acting
sequence elements have been identified which promote rapid decay via poly(A) tail
shortening such as the adenylate/uridylate-rich sequences found in the 3’-UTR of c-fos
(194).  Thus, the poly(A) tail plays a protective role in cells.
The majority of eukaryotic gene transcription units possess a single
polyadenylation signal.  Recently, there have been many reported examples of
transcription units with multiple poly(A) sites which result in more than one RNA species
(196).  Use of alternative poly(A) sites can positively or negatively impact the final
amount of protein product per unit precursor RNA transcribed.  The current examples are
mainly a result of different stages of development or growth state of the cell or tissue.
Dihydrofolate reductase (DHFR) is an extreme example of a gene with multiple poly(A)
sites, with seven sites spread over a 5 kb sequence.  Transcription proceeds through all
seven and terminates 1 kb downstream of the last one (197).  Thus, multiple forms of the
mRNA arise by alternative polyadenylation sites, not a result of transcription termination
between the sites.  A different distribution of these DHFR mRNAs is observed in
growing versus resting cells (198).  It is thought that different mRNAs which are the
result of alternative poly(A) site usage may influence protein expression through
differences in stability or translation efficiency of the individual transcripts.
Pre-mRNA instability
Another example of nuclear posttranscriptional regulation involves nuclear
stability of the pre-mRNA or processed transcript.  Fibronectin is regulated in this
manner.  Fibronectins are large glycoproteins that play roles in cell adhesion, cell
morphology, wound healing, cellular migration and oncogenic transformation.  Down-
regulation of fibronectin protein and mRNA levels by transformation of TE-85 cells, a
human osteosarcoma cell line, with H-ras (199) or up-regulation by treatment of a human
fibrosarcoma cell line, HT-1080, with dexamethasone (200) occurs by changes in the
accumulation of nuclear pre-mRNA in the absence of transcription.  Mechanisms that
would result in changes in accumulation of nuclear RNA include alteration in RNA
processing (splicing or polyadenylation) or alterations in the stability of the transcript in
the nucleus.  The length of the poly(A) tail or the site of polyadenylation were not
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affected by either treatment.  In addition, altered splicing was ruled out as a potential
mechanism.  These results suggest that decreased stability of the processed nuclear
fibronectin RNA is involved in the regulation by H-ras, whereas increased stability of the
unprocessed nuclear fibronectin RNA is involved in regulation by dexamethasone.
To further characterize this mechanism of regulation, a search for cis-acting
sequences mediating the dexamethasone induction was done using transfection analysis
with minigene constructs.  The cis-acting sequences mediating the dexamethasone
induction are thought to reside in intronic regions of the gene since no elements were
found in the 8 kb mRNA.  Experiments to identify elements mediating the H-ras
inhibitory effect have not been done.  This type of nuclear regulation is not unique to
fibronectins.  Another example of regulation in this manner is the estrogen down-
regulation of the peptidylglycine -amidating monooxygenase gene which is a
bifunctional enzyme involved in the posttranslational processing of many prohormones
and neuropeptides (201).  The precise mechanism by which the stability of this nuclear
RNA is controlled has not been established.  It is hypothesized that a putative
destabilizing protein binds to either a specific sequence or secondary structure in these
transcripts.  These cis-and trans-acting factors have not been identified.
Nuclear matrix
There is an emerging recognition that gene regulatory mechanisms are
functionally linked to nuclear architecture.  In this regard, the nuclear matrix is thought to
be involved in gene regulation.  In 1974, Berezney and Coffey coined the term “nuclear
matrix” and speculated on its function (202).  The nuclear matrix is a structural
component of the cell which is composed of proteins and RNA which form tube-like
structures.  These structures have been hypothesized not only to function as an anchor for
actively transcribed chromatin via matrix attachment regions, but also to direct newly
synthesized RNA into the pathway for processing and transport into the cytoplasm.  This
idea is based on immunocytochemical studies which demonstrate the co-localization of
key processing proteins to the specific nuclear domains referred to as “speckles” or
interchromatin granules (203-205).  Using fluorescently-tagged antibodies and probes,
splicing accessory proteins associate with both the matrix and the hyperphosphorylated C-
terminal domain of RNA polymerase II (205).
Association of the nascent transcript to the nuclear matrix, the site of its
processing, and then transport to the nuclear membrane following processing is a
potential site for regulation.  Regulation of the alkaline phosphatase gene is thought to be
stimulated in this manner by retinoic acid (206).  The liver/bone/kidney isoform of this
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enzyme is found mainly in osteoblast cells and is likely to be involved in bone
mineralization.  Tissue-specific regulation (207) or regulation by retinoic acid (206) of
the liver/bone/kidney alkaline phosphatase gene involves changes in the amount of
nuclear pre-mRNA without significant changes in transcriptional activity.  In order to
determine the influence of retinoic acid on the nuclear processing of alkaline phosphatase,
Zhou et al. (206) fractionated the nuclear compartment to isolate RNA from the nuclear
matrix, DNase I/high salt eluate, and nuclear membrane of rat pre-osteoblastic UMR 201
cells.  The results demonstrate that mature (spliced) alkaline phosphatase mRNA
accumulated in the non-matrix fractions of retinoic acid-treated cells at a 100-fold greater
level than in control cells.  This suggests that nuclear processing of the pre-mRNA only
occurred in retinoic acid treated cells, thus processing of alkaline phosphatase pre-mRNA
is enhanced by retinoic acid.  It is thought that enhanced stability of the nuclear RNA on
the nuclear matrix is involved, however, this was not formally tested.  More recently, it
was demonstrated that regulation of other genes affected by retinoic acid such as the
osteopontin gene, a phosphorylated glycoprotein secreted by osteoblasts and osteoclasts,
occurs through the same type of mechanism (208).  The key to understanding these
findings is determining if the RNA transcript is blocked from association with the nuclear
matrix and thereby the processing reactions versus if the transcripts undergo selective
decay during processing.  These experiments remain to be done.
The emerging concept that regulatory components of gene expression must be at
the right place in the nucleus at the right time in order to mediate the proper control
seems to be gaining supportive evidence.  Recent advancements in high resolution in situ
hybridization techniques and immunofluorescence analysis will provide new insights into
the intranuclear distribution of genes and regulatory factors to more fully understand this
concept.  It is unclear if this will be a common organizational principle of efficient gene
expression or if it will be gene-specific.
Nonsense-mediated decay
mRNAs can also be destabilized by the presence of nonsense codons.  Nonsense
codon recognition takes place during protein synthesis and involves cytoplasmic
ribosomes.  Thus, mRNA turnover and translation appear to be directly linked.  This type
of mRNA decay is initiated by deadenylation-independent decapping and subsequent 5’
to 3’ decay of the transcript.  Nonsense-mediated decay occurs in all eukaryotes however
the enzymes involved have only been identified in yeast (209-211).  It appears that there
are two potential cellular pathways that degrade nonsense-containing mRNAs (212).
Results from studies in yeast and mammalian cells are consistent with the hypothesis that
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accelerated turnover of nonsense-containing mRNAs is attributed to cytoplasmic events
that are concurrent with mRNA translation (213,214).  A second decay pathway exists in
mammalian cells in which certain mRNAs are degraded in the nucleus due to the
presence of nonsense codons.  The degradation of nonsense-containing mRNAs
synthesized from the human triose phosphate isomerase (TPI) gene, T-cell receptor-
gene, the hamster dihydrofolate reductase gene, the v-src gene, the mouse major urinary
protein and the human -globin gene is consistent with the hypothesis that their
degradation is associated with the nucleus.  Thus, it appears on the surface that there are
two independent nonsense-mediated mRNA decay pathways, nuclear and cytoplasmic.
The results reported in yeast versus mammalian cells can be rectified if in mammalian
cells, following mRNA export to the cytoplasm but still on the outside of the nucleus, the
nonsense-containing transcript forms an aberrant ribonucleoprotein particle (RNP) that is
susceptible to decay.  The biochemical fractionation of these mRNAs with the nuclear
component may reflect a tight association of mRNPs with the outside of the nucleus.
The effect of nonsense mutations on nuclear-localized decay of TPI has been
analyzed in the greatest detail.  An anemia-inducing mutation which converts a CGA
arginine codon to a TGA nonsense codon is responsible for this decay (215).  The
presence of this nonsense codon causes premature translation termination and also results
in a 5-fold decrease in TPI mRNA.  Furthermore, the results of inhibiting RNA synthesis
with actinomycin D demonstrated that the half-life of a TPI mRNA with a normal
termination codon versus one with a premature nonsense codon was not different.  This
suggests that the decrease in amount of TPI mRNA with a premature termination codon is
not attributable to an increase in the rate of cytoplasmic mRNA decay (216).  Instead, it
was shown to be characteristic of both nuclear and cytoplasmic mRNA fractions of the
cell (217).  In addition, changes in gene transcription or splicing were not observed.
Nucleus-associated RNA can be located within the nucleoplasm, associated with the pore
or almost fully exported and not yet released from the nucleus.  The exact location of the
nucleus-associated mRNA has not been determined.
Three models have been proposed to account for how premature stop codons are
recognized while nucleus-associated (212).  All the models require that RNA containing
premature termination codons be “marked” in some manner.  The first model is a
translational translocation model which suggests that translation begins as soon as the
mRNA coding region emerges from the nucleus.  The translating ribosomes facilitate
splicing of the remaining portion of the pre-mRNA and enhance export.  Premature stop
codons may slow this process thereby degrading some of the pre-mRNA.  The second
model assumes that the fully spliced mRNA is translated as it emerges from the nucleus,
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the 5’-end first.  The presence of a premature stop codon would interfere with this process
and promote rapid decay of nucleus-associated mRNA.  The final model is a nuclear
scanning model in which an unidentified scanning process within the nucleus recognizes
and degrades mRNAs containing premature stop codons.  It is unclear whether every
mRNA with a nonsense codon is degraded in the same manner.  The pathway of
nonsense-mediated decay may depend on the cell type where this is occurring or the
actual gene product itself.
The model that has the most supporting evidence is the nuclear scanning model.
Evidence from experiments done using the TPI gene have led to support of this model.  In
this respect, at least one intron is required which implicates nuclear splicing as an effector
of translation (218).  The most convincing explanation of this model that has been
proposed is that all exon-exon junctions within a mRNA from a multi-intron gene may be
“marked” with a remnant of the splicing machinery.  The decision whether translation
termination occurred prematurely is made by the putative scanning complex.  The scanner
then must interact with a properly positioned downstream “marked” junction.  The
proposed nuclear scanning mechanism may be some component of the translation
termination complex or it may be a completely distinct complex.  The scanner appears to
have limits to the distance to which it can scan and recognize mRNAs which are marked
for decay.  In this respect, nonsense mediated decay requires the “marked” intron to reside
at least 50 nt downstream but less than 550 nt downstream of the nonsense codon (219).
The identification of trans-acting factors will be required to resolve the details of this
mechanism.  Splicing factors have been implicated in this model since several factors
have been shown to shuttle from the nucleus to the cytoplasm (220,221).
This mechanism was originally thought to eliminate “imperfect messages” which
contain premature translation termination codons which can code for nonfunctional or
harmful polypeptides.  In support of this hypothesis, there are well over 200 genetic
disorders that result from premature translation termination (222).  However, recent
evidence suggests that this path may contribute to the regulation of mRNA half-life for
normal mRNAs, such has been reported for mRNAs involved in normal telomere
chromatin function and/or telomere control length (223).
Iron response elements
There are many well characterized examples of posttranscriptional regulation in
the cytoplasm.  An intriguing system showing posttranscriptional gene control is the
regulation of cellular iron metabolism in higher eukaryotes.  Excess iron leads to an
increase in translation of ferritin mRNA and a decrease in stability of the transferrin
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receptor mRNA mediated by cytosolic proteins called iron response element binding
proteins (IRBP).  The opposing effects aid in controlling iron homeostasis in the cell.
The IRBPs bind to iron response elements (IRE) in the 5’-UTR of ferritin mRNA and in
the 3’-UTR of transferrin receptor mRNA (224-226).  The IRP has been shown to interact
with ferritin and transferrin receptor transcripts, via a “sulfhydryl switch” mechanism
(227).  According to this model, iron concentrations in the cell are able to alter the
available sulfhydryl groups in the IRP that are involved in binding to the IRE.  The switch
occurs when an iron-sulfur cluster in the protein becomes saturated with iron when iron is
abundant.  This in turn leads to a protein conformational change which prevents binding
to the response element.  On the other hand, when iron concentration is low, the iron-
sulfur cluster disassembles and allows a protein conformation which has strong affinity
for the IRE.  This mechanism was proposed after the discovery of two forms of the IRBP,
a high affinity reduced form and a low affinity oxidized form.  Additional evidence
comes from the finding that sulfur was required in experiments to demonstrate IRBP
binding to the IRE (228,229).
Endonucleolytic cleavage of some mRNAs is regulated by RNA-binding proteins
that bind in the vicinity of the cleavage sites and render them inaccessible to nucleolytic
attack.  This type of control is also observed in iron metabolism.  For example, five IREs
are located within a 678 nt fragment of the 3’-UTR of transferrin receptor mRNA and a
functional endonucleolytic cleavage site is situated between each of the IREs (230).  The
binding of the IRBP to the IRE prevents access of the nuclease to the cleavage site.
When iron concentration is increased, the IRE-IRBP interaction decreases and the
endonucleolytic cleavage can then occur in the transferrin receptor transcript, resulting in
a decrease in stability.  This mechanism is not unique to iron regulation.  Endonucleolytic
cleavage sites have also been identified in coding region sequences of c-myc and Xenopus
laevis albumin mRNA in addition to those identified in the 3’-UTR of transferrin receptor
(231,232).
Coding region stability determinants
Sequences within coding regions have been identified in many genes to regulate
stability such as in the c-fos, c-myc, human interferon, and -tubulin genes.  A common
sequence motif among these examples has not been identified.  In some cases these
sequences do not bind to trans-acting factors.  Additionally, most examples of genes with
coding region stability determinants also have additional stability factors in other areas of
the gene.  This is the case for c-fos and c-myc.  c-myc and c-fos contain stability
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determinants in the 3’-UTRs of their messages in addition to those found in the coding
region.
The identification of coding region determinants in c-fos and c-myc was shown by
deletion and/or replacement of the 3’-UTRs of these genes with an unrelated sequence
(233,234).  The 3’-UTRs of these genes are known to contain the adenylate/uridylate rich
instability determinants.  The presence of a heterologous UTR did not result in an
increase in half-life of the mRNA which suggested the presence of additional instability
determinants besides those in the 3’-UTR.  To further identify the additional regulatory
sequence in c-fos, the coding region of c-fos was inserted into the globin mRNA which is
very stable with a half-life of greater than 8 h.  This resulted in a new half-life of less than
30 min (235).  This 320 bp coding region determinant is 391 to 709 nt downstream of the
translation initiation codon.  In addition, gel mobility shift assays and UV-crosslinking
assays have identified two cellular proteins which bind specifically to this region (236).
The c-myc mRNA coding region determinant has been identified more precisely to a 180
nt fragment (237).  A trans-acting protein has also been shown to bind to this C-terminal
coding region in vitro (238).  This protein may function as a stabilizing factor by binding
to the c-myc coding region determinant and protecting the RNA from attack by
ribonucleases.  Thus, it appears that mRNAs can contain two or more well separated
stability determinants, each of which most likely specifies a distinct decay pathway or a
distinct response to a regulatory factor.
Adenylate/Uridylate rich elements
Adenylate/Uridylate-rich elements (AUREs) found in the 3’-UTR of many labile
cytokine, transcription factor, and proto-oncogene mRNAs represent the most common
RNA stability determinant in mammalian cells.  AUREs play a critical role in regulation
of gene expression.  AUUUA is a common sequence motif that is repeated several times
but the presence of this sequence alone is insufficient to cause decay.  Many AURE-
containing mRNAs are degraded by a sequential pathway involving removal of the
poly(A) tail followed by degradation of the mRNA transcript (239).  Destabilization is
thought to occur in c-fos (240).  c-fos  mRNA is one of the least stable mammalian
messages (t1/2= 30 min).  When the ARE from c-fos is replaced within the 3’-UTR of a
stable mRNA, the normally stable transcript is destabilized.  In a different type of
experiment, point mutations or deletion of these ARE sequences results in stabilization of
the c-fos mRNA.  In addition, deletion of the AURE in the 3’-UTR of c-os increases its
oncogenic power (241) suggesting that this element may play a role in cellular
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transformation due to the stability effect.  Since AURE-mediated decay is linked to cell
transformation and oncogenesis, elucidation of its mechanism of action is important.
A detailed understanding of how AUREs function requires the identification of
trans-acting proteins that interact with the AURE.  Many such factors have already been
identified and is this list is constantly growing.  Recently, a family of ARE-binding
proteins have been identified which bind to AUREs on many mRNAs to decrease their
stability (242).  This family is formed by alternative splicing of a single gene and
functions as part of a multi-subunit complex to promote turnover (242).  Other examples
of AUREs which function as RNA destabilizing elements have been identified in c-myc,
interferon and human granulocyte-monocyte colony-stimulating factor (243-245).
AUREs affect mRNA half-lives in different ways by interacting with different regulatory
factors whose expression, in turn, depends on treatment.  Thus, the signal transduction
pathway that affects protein binding to the AUREs are probably distinct for each gene.
A variation of the AUREs is a class of elements referred to as uridine-rich
elements (URE).  A URE has been identified in the c-fos gene in addition to the AURE,
which has been shown to promote rapid deadenylation.  In c-fos, four different URE
binding proteins have been identified which bind to these U-rich sequences.  The
pathways for AURE-mediated decay and URE-mediated decay have begun to be
identified which show that deadenylation is the first critical step in the decay of mRNAs
containing these elements (246).  However, deadenylation occurs by two distinct
pathways because mRNAs containing AUREs have different decay intermediates than
those containing UREs.  AURE-mediated mRNA decay results in intermediates with
poly(A) tails of 30-60 nt whereas URE-mediated decay results in poly(A) minus decay
intermediates.  It is thought that differences in organization of some sequence features,
such as the spacing between AUUUA sequences and U-rich sequences, could result in the
binding of different RNA-protein complexes or different ways of organizing the same
factors.  These distinct complexes could directly influence or modulate the processivity of
a ribonuclease or recruit kinetically distinct ribonucleases for each of these pathways.  c-
fos has both of these types of elements in addition to a coding region stability determinant
therefore this gene may use distinct pathways in response to different factors.  Thus, the
stability of a given mRNA can be controlled by specific intrinsic nucleotide sequences




G6PD expression occurs by a nuclear posttranscriptional event.  While dietary fat
coordinately inhibits multiple enzymes in intermediary metabolism at a pre-translational
step (5), the mechanisms involved vary significantly between genes.  Regulation of G6PD
expression at a posttranscriptional step would permit enhanced expression in tissues such
as liver when the need for lipogenesis increases, and uniform expression in all cells for its
role in cellular detoxification and nucleotide biosynthesis.  Regulation of G6PD at an
exclusively posttranscriptional step is quite unique compared to the other lipogenic
enzymes which seem to have both transcriptional and posttranscriptional components to
their regulation.
Posttranscriptional control of mRNA is an integral component of regulated gene
expression and there are many ways in which the amount of a specific transcript can be
affected by these pathways.  The stability of a given mRNA can be controlled by specific
intrinsic cis-acting RNA sequences and regulated by trans-acting RNA binding proteins
that are either mRNA specific or bind to many RNAs.  Furthermore, the half-life of many
mRNAs can fluctuate in response to developmental or environmental stimuli such as
nutritional or hormonal factors, cytokines and viral infection.  Identification of the
regulatory mechanism involved in the regulation of G6PD by dietary fat will aid in our
knowledge of novel posttranscriptional mechanisms as well as understanding the
molecular basis for many diseases associated with the consumption of dietary fat.  This
may lead to the engineering of new “low-fat” foods or new targets for drug discovery.
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CHAPTER 2.  POLYUNSATURATED FATTY ACIDS INHIBIT THE
EXPRESSION OF THE GLUCOSE-6-PHOSPHATE DEHYDROGENASE GENE
IN PRIMARY RAT HEPATOCYTES BY A NUCLEAR
POSTTRANSCRIPTIONAL MECHANISM
*This chapter has been reproduced with permission from the Journal of Lipid Research.
Stabile, L. P., S. A. Klautky, S. M. Minor, and L. M. Salati.  1998.  J. Lipid Res.  39:
1951-1963.
(Fig. 3A was done entirely by S. Klautky)
Introduction
Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49) is the rate-determining
enzyme of the pentose phosphate pathway, which provides a source of NADPH for many
biosynthetic reductive reactions and ribose-5-phosphate for nucleic acid synthesis.  The
reaction catalyzed by G6PD provides 50-75% of NADPH needed for fatty acid
biosynthesis in rat liver (1).  All cell types contain G6PD activity; however, regulation of
the enzyme only occurs in liver and adipose tissue (2,3).  G6PD activity in the regulated
tissues correlates with the rate of fatty acid biosynthesis and thus it is a member of the
lipogenic family of enzymes.  Like other lipogenic enzymes, G6PD is regulated by both
nutritional and hormonal stimuli.  For example, when rodents are fed a high-
carbohydrate, low-fat diet after a period of starvation, G6PD activity increases 10- to 16-
fold (3,4).  Conversely, G6PD activity decreases 80% in mice and rats consuming a high-
fat diet versus those fed a low-fat diet (5,6).  Hormonal aspects of G6PD regulation
include a decrease in G6PD activity in diabetic and adrenalectomized rats that is restored
by hormone replacement (7).  In addition, in primary rat hepatocytes, insulin increases
G6PD activity in a dose-dependent manner (8).  Curiously, treatment of rat hepatocytes
with dexamethasone does not change G6PD activity (8), suggesting that the effect of
adrenalectomy is indirect.
Regulation of G6PD by nutritional factors occurs at a nuclear posttranscriptional
step.  In this regard, the 80% decrease in G6PD mRNA amount is accompanied by an
80% decrease in nuclear precursor mRNA (pre-mRNA) for G6PD in the nucleus.
Similarly, the increase in G6PD mRNA due to refeeding starved mice is accompanied by
comparable increases in the amount of G6PD pre-mRNA (9).  Nevertheless, the rate of
transcription of the G6PD gene is not altered despite large changes in the abundance of
pre-mRNA (5).  Further characterization of the regulation of the G6PD gene indicates
that transport of the mRNA from the nucleus to the cytoplasm and splicing of the primary
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transcript are not regulated steps in its expression.  Thus, regulation of the amount of
G6PD pre-mRNA is probably occurring very soon after transcription of the primary
transcript.
The nuclear posttranscriptional regulation of G6PD contrasts with the large
changes in transcriptional activity observed with other lipogenic enzymes, such as fatty
acid synthase and stearoyl-CoA desaturase I (10,11).  Yet, changes in pre-mRNA stability
may be a common mechanism for all these genes.  In this regard, S14, a protein of
unknown function that is thought to be involved in lipogenesis, undergoes large
transcriptional changes in response to dietary carbohydrate and polyunsaturated fatty
acids (10).  In addition to these transcriptional changes, dietary carbohydrate enhances the
accumulation of processing intermediates of S14 pre-mRNA (12,13) suggesting that
enhanced expression of the S14 gene involves increased efficiency of the processing of its
pre-mRNA.
The goal of these studies is to further analyze the mechanism by which
polyunsaturated fat inhibits G6PD expression.  Studies in the intact animal are hampered
by an inability to distinguish a direct effect of fatty acids on expression of a gene from an
indirect effect due to changes in the hormonal environment of the animal.  Cell culture
models provide a mechanism to control the hormonal environment while examining the
action of fatty acids.  Incubation of primary rat hepatocytes with polyunsaturated fatty
acids mimics the effect of dietary fat on the transcription of S14 and pyruvate kinase
(14,15).  The ability of this cell model to mimic posttranscriptional actions of
polyunsaturated fatty acids has not been described.  In this paper we demonstrate that the
action of polyunsaturated fatty acids on G6PD pre-mRNA accumulation in rat
hepatocytes mimics the action of dietary fat in the intact animal both qualitatively and
quantitatively.
Materials and methods
Materials.  Williams’ medium E (Gibco-BRL), newborn calf serum (Gibco-
BRL), fatty acids (Nu-Chek Prep), collagenase H (EC 3.4.99.5, Boehringer Mannheim),
insulin (Eli Lilly Research Laboratories), Matrigel (Collaborative Biomedical Research),
Percoll (Sigma), pBluescriptKS+ (Stratagene), RNase-free DNase I (Gibco-BRL), and
RPA II kit (Ambion) were obtained from the indicated sources.  Bovine serum albumin
fraction V (fatty acid-free), -[32P]UTP, 3000 Ci/mmol and -[32P]dCTP, 3000 Ci/mmol
were from ICN Biochemicals.  Other chemicals were from Fisher Biotech or of the
highest purity commercially available.  Rats were purchased from Harlan Laboratories
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(Indianapolis, IN).  Standard chow diet was Harlan Teklad and the fat-free, high-glucose
diet was from Purina Mills.  Rat genomic DNA was obtained from Clontech.
Animal care and cell culture.  Male Sprague-Dawley rats (approximately 200 g)
fed on a standard chow diet were used for all experiments.  Rats used for dietary
experiments were starved for 24 h or starved for 24 h and then refed a high-glucose, fat-
free diet (5) for 15 h prior to sacrifice.  Rats were starved for 48 h prior to use as
hepatocyte donors.
Hepatocytes were isolated by a modification of the technique of Seglen (16).  The
livers were perfused with 350 ml of calcium-free buffer (0.14 M NaCl, 6.7 mM KCl, 0.02
M HEPES, pH 7.4, 25 mM glucose, 250 µM EGTA) at 40 ml/min followed by 100 ml of
a buffer containing collagenase (67 mM NaCl, 6.7 mM KCl, 0.1 M HEPES, pH 7.4, 6
mM CaCl2.2H2O, 25 mM glucose, 1 mg/ml collagenase H, 0.05 mg/ml trypsin inhibitor).
The hepatocytes were then teased from the capsid of the liver and washed into cold, well-
oxygenated Williams’ medium E supplemented with 23 mM HEPES, pH 7.4, 26 mM
sodium bicarbonate, penicillin (100 U/ml), streptomycin (100 µg/ml), and gentamicin (50
µg/ml).  Glucose was added to a final concentration of 27 mM.  The cells were spun
through a Percoll gradient for 10 min at 50 X g to remove non-parenchymal cells (17).
Hepatocytes (4 X 106) were placed in 60 mm Primaria dishes preincubated (37°C, 5%
CO2) with medium containing 5% newborn calf serum.  Cell viability in all experiments
was 90% or greater as estimated by Trypan Blue (0.4%) exclusion.  After 4 h, the medium
was replaced with serum-free medium.  After an additional 16 h of incubation, the
medium was replaced with medium containing the treatments indicated in the figure
legends and a Matrigel overlay (0.3 mg/ml) (18).  Subsequently, the medium was changed
every 12 to 24 h to one of the same composition but without Matrigel.  The hepatocytes
were maintained in a humidified chamber at 37• C in 5% CO2 /95% air.  Fatty acids were
bound to bovine serum albumin (19).  The fatty acid (4 mM)-albumin (1 mM) stocks
contained butylated hydroxytoluene (0.01%) and Williams’ medium E contains -
tocopherol phosphate, disodium (10 µg/L) to minimize oxidation of fatty acids.
Thiobarbituric acid (TBA) assay.  The TBA assay was performed as described
by Hostmark and Lystad (20) with minor modifications.  Phenol red typically found in
cell culture medium interfered with this assay, thus for these experiments Williams’
medium E without phenol red was used.  To measure TBA reactive material in the cell
culture medium, 4.5 ml of a 0.4% TBA solution in water was mixed with 0.4 ml of
medium from hepatocytes incubated with various fatty acids.  Glacial acetic acid (100 µl)
containing 0.5% butylated hydroxytoluene was added, the mixture was vortexed
vigorously, and heated to 100• C for 20 min.  Insoluble material was removed by
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extraction with 3 ml of chloroform/methanol (5:1, v/v).  The absorbance at 532 nm of the
aqueous phase was determined.  The amount of TBA reactive material was calculated
using the molar extinction coefficient (156,000 M-1cm-1).
Measurement of G6PD activity.  Hepatocytes were prepared as described above
and incubated 72 h with the treatments indicated in the figure legends.  Cells were
washed one time with phosphate-buffered saline, and lysed by three cycles of freezing
and thawing in 0.5 ml of buffer (50 mM Tris-acetate, pH 7.4, 300 mM mannitol, 5 mM
dithiothreitol) per 60 mm Primaria plate.  The lysates were centrifuged for 10 min at
11,000 x g.  Supernatants were used for measurement of G6PD enzyme activity (8) and
total protein concentration (21).  G6PD activity is reported as mU/mg protein in the cell
supernatant; 1mU equals 1nmol of NADPH produced per minute.  Statistical analysis was
with ANOVA and t-test.
Isolation of total RNA and Northern analysis.  Total RNA from 2-3 plates per
treatment was isolated by the method of Chomczynski and Sacchi (22).  The denatured
cell mix was forced through an 18 gauge syringe two to three times to sheer genomic
DNA.  Quantitation of RNA using Northern analysis was done as previously described
(5).
Isolation of nuclear RNA.  Nuclei from hepatocytes were isolated by a
modification of the method of Leppard and Shenk (23).  Hepatocytes and medium from
15-20 plates per treatment were collected into 50 ml centrifuge tubes and the cells
pelleted in a Beckman JS 4.2 rotor at 490 rpm (50 X g) for 5 min.  The cell pellet was
washed two times with ice-cold phosphate-buffered saline, then homogenized in 3 ml of
isotonic buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 175 µg
phenylmethylsulfonyl fluoride/ml, 0.6% nonidet NP-40) by 12 strokes in a Dounce
homogenizer using a tight-fitting pestle.  The homogenate was incubated on ice for 5 min.
Nuclei were pelleted in a Beckman JS 4.2 rotor at 2000 rpm (800 X g) for 5 min at 4• C
and washed one time with 2 ml of isotonic buffer without nonidet NP-40.  RNA was
purified from the final nuclear pellet by the method of Chomczynski and Sacchi (22); 3
ml of denaturing solution were used per nuclear pellet.  The denatured nuclear RNA mix
was forced through an 18 gauge syringe five times to sheer genomic DNA.  In
experiments using intact rat liver (Fig. 2), nuclei were purified through a 2 M sucrose
cushion as previously described (5) prior to isolation of nuclear RNA.
Nuclear run-on assays and DNA probes.  Nuclei were isolated from hepatocytes
using the method of Leppard and Shenk (23) as described above.  In one experiment,
nuclei were isolated by the method of Milsted (24).  The same results were obtained in
the run-on assays regardless of the method of nuclei preparation.  The final nuclear pellet
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was resuspended and washed into nuclei storage buffer (50 mM HEPES, pH 7.4, 75 mM
NaCl, 0.1 mM EDTA, 5 mM dithiothreitol, 0.12 mM phenylmethlysulfonyl fluoride, and
50% glycerol).  Nuclei were purified from intact rat liver by centrifugation through a 2 M
sucrose cushion as previously described (5).  The nuclei were stored at -70• C in 100 µl
of storage buffer prior to use in a nuclear run-on assay.
The nuclear run-on assay was performed on both hepatocyte and liver nuclei as
previously described (25,5).  DNA used as probes were obtained as follows:  mouse
G6PD cDNA (pMZ3) from M. Zollo (26), rat phosphoenolpyruvate carboxykinase
(pPCK10) cDNA from R. Hanson (27), mouse albumin cDNA (pmalb-2) from S.
Tilghman (28), rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
(pRGAPDH1) from F. Rottman (29), mouse stearoyl-CoA desaturase I cDNA (pC3) from
J. Ntambi (30), rat fatty acid synthase cDNA (pFAS-17) from S. Clarke (31).  The G6PD
cDNA probe is the BamHI (exon 2) to XbaI (exon 13) fragment of pMZ3 which was
subcloned into pBluescriptKS+ thereby eliminating exon 1 which is GC-rich, and most of
exon 13 which is dissimilar between rats and mice.
Probe design for ribonuclease protection assay (RPA).  Two probes were
designed for use in the ribonuclease protection assay (Fig. 1).  The first probe, intron 3-
exon 4, was derived from PCR amplification of rat genomic DNA using primer 1, 5’-
GGGGTACCGGTAATATCTCTACACTACCCCCCAATC-3’ and primer 2, 5’-
GGAATTCGCTCACTCTGTTTGCGGATGTC-3’.  Primer 1 contained a KpnI
restriction site at its 5’ end (underline) for subcloning of the PCR amplified product into
pBluescriptKS+ and the remaining sequence is from intron 3.  Primer 2 contained an
EcoRI site at its 5’ end (underline) and the G6PD sequence begins 11 nt from the end of
exon 4.  The second probe, exon 9-intron 9, was derived from PCR amplification of rat
genomic DNA using primer 3, 5’-GGGGTACCCAGAGGTGGAAACTGACAAC GTG-
3’ and primer 4, 5’-GGAATTCTAGCCCTCCTTCTCCAGCATTC-3’.  The same
restriction sites are present as for the previous probe.  Primer 3 contained exon 9-specific
sequences beginning 22 nt 3’ from the start of exon 9.  Primer 4 contained intron 9-
specific sequences.
The DNA fragments, following PCR amplification, were subcloned into
pBluescriptKS+ and the authenticity of these sequences was verified by sequencing.  The
subclones were linearized with HindIII and used in an in vitro transcription reaction.  The
transcripts produced with T7 polymerase were designed to be larger than the protected
fragments so that incompletely digested probe could be differentiated from the target
signal in the ribonuclease protection assay.  As a control for strand-specific hybridization,
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Figure 1.  Probes and predicted fragments for the ribonuclease protection assay.  The top
line represents a simplified diagram of the G6PD primary transcript showing 3 of the
genes 13 exons.  The lower lines represent G6PD specific mRNA fragments that are
detected in the ribonuclease protection assays by specific G6PD probes.  Two probes
were designed to hybridize across intron-exon boundaries of target mRNA such that pre-
mRNA with and without introns could be detected in the assay.  The first probe (intron 3-
exon 4) was designed to cross the intron 3 - exon 4 boundary and protects a 204 nt
fragment of pre-mRNA containing intron 3.  In addition this probe recognizes processed
transcripts (97 nt fragment) that have undergone splicing of intron 3.  The second probe
(exon 9 - intron 9) spans the exon 9- intron 9 boundary.  It protects a 286 nt fragment of
the transcript containing intron 9, and nuclear mRNA without intron 9 (165 nt fragment).
Exon 1 Exon 4 Exon 9




RNA probes were also generated from the T3 promoter in pBluescriptKS+ which resulted
in a probe whose sequence was identical to G6PD mRNA (sense probe) and thus should
not hybridize to cellular RNAs.  No bands were detected in a ribonuclease protection
assay using these probes (data not shown) therefore only T7-generated probes could
hybridize to G6PD mRNA.
Ribonuclease protection assay.  Antisense RNA probes were synthesized in an
in vitro transcription reaction.  Template DNA (0.5 µg) was added to a reaction mixture
containing 40 mM Tris-HCl, pH 7.5, 6 mM MgCl2, 2 mM spermidine, 10 mM NaCl, 10
mM dithiothreitol, 14 U RNasin, 400 µM each ATP, CTP, and GTP, 20 µM cold UTP,
20 U T7 RNA polymerase and 50 µCi -[32P]UTP (sp. act. 3000 Ci/mmol) and incubated
at 37• C for 1 h. RNase-free DNase I (100 U) was added and the reaction was incubated
for 15 min at 37• C.  The probes were purified in a 5% denaturing polyacrylamide gel
and eluted overnight at 37• C in 0.5 M ammonium acetate, 1 mM EDTA, and 0.2% SDS.
Ribonuclease protection assays were performed using the RPA II kit.  Nuclear or
total RNA (25 or 30 µg) was hybridized to 2 X 104 cpm of 32P-labeled RNA  in 20 µl of
hybridization solution (80% deionized formamide, 100 mM sodium citrate, pH 6.4, 300
mM sodium acetate, pH 6.4, 1 mM EDTA) at 45• C for 16 h.  Following hybridization,
the solution was treated with a mixture of 0.5 U RNase A and 20 U RNase T1 for 30 min
at 37• C.  The resulting hybridization products protected from RNase digestion were
separated in a 5% denaturing polyacrylamide gel.  The gel was dried and placed in a
storage phosphor cassette for 1 to 3 d.  Images were quantified using ImageQuaNT
software by Molecular Dynamics.
Results
Effect of starvation and refeeding on transcriptional activity of G6PD in rat.
Refeeding starved mice results in a 15-fold or more increase in G6PD mRNA,
while the addition of polyunsaturated fat to a high-carbohydrate diet results in an 80%
decrease in G6PD mRNA (5).  In mice, dietary-induced changes in G6PD mRNA
accumulation are caused by changes in the amount of pre-mRNA for G6PD via a
posttranscriptional regulatory mechanism in the nucleus (9).  Mouse hepatocytes in
primary culture do not provide a hormonally-responsive system to study the molecular
basis for this regulation (32; S. A. Klautky and L. M. Salati, unpublished).  In contrast,
G6PD activity is regulated by both insulin and fatty acids in rat hepatocytes in primary
culture (8).  Prior to choosing rat hepatocytes as a model to further define the molecular
basis of G6PD regulation, we verified that regulation of G6PD expression by diet
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occurred by a posttranscriptional regulatory mechanism as observed in mice.  No
difference in G6PD transcription was observed in rats that were starved versus starved
and then refed a high-carbohydrate diet (Fig. 2A).  In contrast, refeeding increased the
transcription of the stearoyl-CoA desaturase I (pC3) and fatty acid synthase (FAS) genes,
by 85- and 77-fold, respectively, and transcription of the phosphoenolpyruvate
carboxykinase gene was inhibited by 93%.  Thus, the expected transcriptional changes
were observed for genes regulated at the level of transcription while regulation of G6PD
expression is occurring primarily at a posttranscriptional step in rats as in mice.
We next measured nuclear pre-mRNA for the G6PD gene using a ribonuclease
protection assay and probes that hybridized across two different intron/exon boundaries in
the G6PD primary transcript (Fig. 1).  Because the G6PD gene contains 13 exons and the
primary transcript is 18 kb in length it cannot be examined in total.  The probes represent
discrete locations within the primary transcript and permit quantitative analysis of the
amount of pre-mRNA.  The intron 3-exon 4 probe hybridized across a 3’-splice site and
the exon 9-intron 9 probe hybridized across a 5’-splice site.  RNase digestion of each
hybrid of probe and target RNA resulted in two protected fragments.  These included
RNA containing the intron and RNA from which the intron had been spliced.  The 204
and 286 nt bands represented pre-mRNAs that contained introns 3 and 9, respectively
(Fig. 2B).  The 97 and 165 nt bands represented pre-mRNAs from which introns 3 and 9,
respectively, had been spliced.  Protected fragments representing only intron 9 (121 nt)
and the exon 4 and intron 3 lariat (33; 133nt) also appeared to be detected.  The relative
intensity of these fragments was much less than the bands containing exon sequences.
This may reflect that introns, once spliced, were rapidly degraded in the nucleus.  In some
experiments (Fig. 2B and 6A) a doublet in the intron 3-exon 4 band was observed.  The
sequence at one end of the intron 3-exon 4 probe is AU-rich which may allow local
denaturation of the hybrid making it susceptible to ribonuclease digestion.  This doublet
disappeared when the RNase digestion conditions were altered to use either 50% less
RNase A and RNase T1 or only RNase T1 (data not shown) confirming that the doublet
was due to “breathing” at the ends of the hybrid.
To determine if the abundance of G6PD pre-mRNA was regulated in the rat, RNA
was isolated from the nuclei of the same rats as were used for transcriptional
measurements (Fig. 2B).  In the livers of rats that had been starved for 24 h, G6PD pre-
mRNA was barely detectable.  G6PD pre-mRNA was 18.9- and 19.5-fold higher as
detected by the exon 9-intron 9 and intron 3-exon 4 protected fragments, respectively, in
the livers of rats that had been refed a high-carbohydrate, low-fat diet relative to the rats
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Figure 2.  Effect of starvation and refeeding on expression of G6PD in the rat.  (A)
Nuclei were isolated from the pooled livers of 2 rats that had been starved for 15 h or
from the livers of 2 rats that had been starved for 24 h followed by refeeding a high-
glucose, low-fat diet for 15 h.  Nuclear run-on assays were performed as described in
“Materials and Methods.”  Hybridization to the probes was quantified using
ImageQuaNT.  Quantitation of the hybridization signals for G6PD, vector
(pBluescriptKS+), and ß-actin are listed below each strip.  The values are the integration
units (x 10-2) from ImageQuaNT.  cDNA clones for fatty acid synthase (FAS) and
stearoyl-CoA desaturase I (pC3) were used as positive controls to show transcriptional
activation due to refeeding a high-carbohydrate diet.  A PEPCK cDNA probe was used as
a negative control to show transcriptional inhibition by refeeding.  -actin,
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), albumin, and
phosphoenolpyruvate carboxykinase (PEPCK) cDNA probes were used as controls for
selectivity of the response.  The assay was done in duplicate with identical results.  (B)
Nuclear RNA was isolated from the same batch of nuclei as described above.  G6PD
nuclear RNA (25 µg ) was analyzed using a ribonuclease protection assay and 2 G6PD
specific probes.  M=  RNA Century marker (Ambion), U= Undigested probe
(hybridization of probes to 25µg yeast RNA without subsequent RNase digestion), D=
Digested probe (hybridization to 25µg yeast RNA followed by RNase digestion), S=
nuclear RNA isolated from livers of starved rats, R= nuclear RNA isolated from livers of
refed rats, open arrow= exon 4 and intron 3 lariat protected fragment, closed arrow=
intron 9 protected fragment.  (C)  Quantitation of the signals was done using
ImageQuaNT.  The values shown in the table are the integration units (x 10-2) and the
calculated fold-increase due to refeeding.
64
that had been starved.  Pre-mRNAs in which introns 9 and 3 had been spliced, were
increased 17.3- and 18.9-fold, respectively.  The changes in amount of exon-only
protected fragments were similar to the full-length protected fragments, suggesting that
splicing was not a regulated step.  Thus, refeeding starved rats increased the abundance of
pre-mRNAs for G6PD in the nucleus in the absence of an observable change in
transcriptional activity of the gene.  Thus, the regulated step mediating the effects of
starvation and refeeding on G6PD expression in the rat appears to be the same as that in
the mouse.  Rat hepatocytes should provide a useful model system for further
characterizing the molecular mechanisms involved in regulation of G6PD expression.
Regulation of enzyme activity and mRNA accumulation by glucose, insulin, and fatty
acids in rat hepatocytes in primary culture.
G6PD activity has been shown to be maximally increased by insulin, and this
increase is attenuated by arachidonic acid in rat hepatocytes (8).  To determine whether
fatty acids regulated G6PD at a pretranslational step, mRNA accumulation and enzyme
activity were measured in rat hepatocytes incubated with insulin or insulin and
arachidonic acid.  Incubation with insulin (0.1 µM or 1 µM) for 72 h resulted in a 5.7- to
5.9-fold increase in G6PD activity (Fig. 3A).  Coincubation with arachidonic acid
significantly inhibited (P< 0.05) the insulin dependent increase in G6PD activity by 56%
and 51%, for 0.1 µM and 1 µM insulin, respectively.  These results are consistent with a
previous report (8).  G6PD mRNA accumulation was examined using Northern analysis.
The increase in G6PD activity in hepatocytes incubated with insulin was accompanied by
a 4.2-fold increase in mRNA for G6PD (Figs. 3B & 3C).  This increase in G6PD
expression was not exclusively due to the addition of insulin.  In this regard, incubation
with 27 mM glucose in the medium for 48 h resulted in a 2.9  0.5-fold increase in G6PD
mRNA (n=6); the addition of insulin (0.1 µM) resulted in a further increase in G6PD
mRNA of 1.6  0.06-fold (n=6; Fig. 3B).  Incubation with 250 µM arachidonic acid or
eicosapentaenoic acid decreased the amount of G6PD mRNA by approximately 50%
relative to hepatocytes incubated with glucose and insulin (Fig. 3C).  The concentration
of arachidonic acid used  in these experiments has previously been shown to maximally
inhibit G6PD expression (8).  Arachidonic acid or eicosapentaenoic acid did not inhibit
the increase in G6PD mRNA caused by 27 mM glucose alone (data not shown)
suggesting that inhibition of G6PD expression by fatty acids may be caused by an
inhibition of the action of insulin.  Thus, changes in G6PD enzyme activity due to long
chain polyunsaturated fatty acids were accompanied by comparable changes in the





























































Figure 3.  Effect of insulin, glucose, and arachidonic acid on G6PD enzyme activity and
mRNA accumulation in cultured rat hepatocytes.  (A)  Rat hepatocytes were cultured in
serum-free Waymouth’s 752/1 medium (27 mM glucose).  24 hours after the cells were
plated the medium was changed to one containing various concentrations of insulin and
arachidonic acid (250 µM, premixed, at a 4:1 ratio with BSA) or a control-BSA solution
(BSA prepared without fatty acid).  Matrigel (0.3 mg/ml) was added at the same time.
Subsequently, the media was replaced every 24 h with one of the same composition but
without Matrigel.  After 72 h of incubation, the cells were harvested, lysed by freeze-
thaw, and G6PD enzyme activity was measured in the soluble protein extracts.  The
results are presented as mU/mg soluble protein and are the mean ± SD of n=2
independent experiments each of which had 2 plates per culture treatment.  Time 0
represents the activity in hepatocytes prior to the addition of insulin and fatty acids (24 h
after plating the hepatocytes).  (B)  Rat hepatocytes were isolated and cultured in
Williams’ medium E (11 mM glucose) as described in Materials and Methods.  Twenty
four hours after plating, the medium was replaced with one containing 0.1 µM insulin, 27
mM glucose or 250 µM fatty acids as indicated.  After 48 hours in culture with the
indicated treatments, total RNA was isolated from the hepatocytes.  The amount of G6PD
and GAPDH mRNA in total RNA was analyzed by Northern analysis.  The first two lanes
without treatments represents RNA isolated from hepatocytes after 24h of incubation,
prior to the addition of the treatments (time 0).  The signal for GAPDH was enhanced
1.5-fold over the signal for G6PD using ImageQuaNT.  The size of the mRNAs for G6PD
and GAPDH are 2.3 and 1.8 kb, respectively.  Part B is a representative Northern and Part
C is the mean  the SE of n=8 experiments for the time 0, insulin (0.1 µM insulin and 27
mM glucose), and arachidonic acid (20:4; 250 µM) treatments and n=3 experiments for
the eicosapentaenoic acid (20:5; 250 µM)) treatment.  Quantitation was done using
ImageQuaNT analysis and the results are expressed in relative amounts where the amount
of RNA at time 0 was set to one.
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To determine whether the effect of glucose, insulin and arachidonic acid on G6PD
expression was specific, we also measured the amount of GAPDH and -actin mRNA
with these treatments.  Expression of GAPDH mRNA was consistently increased 2-fold
by insulin and glucose, but the amount of GAPDH mRNA was not changed by incubation
with polyunsaturated fatty acids indicating that the effect of fatty acids was specific (Fig.
3B).  Further, the amount of -actin mRNA did not change with any of the treatments
(data not shown) indicating that insulin, glucose and long chain polyunsaturated fatty
acids do not have generalized positive or negative effects within the hepatocytes.
Time course of the effect of arachidonic acid on G6PD mRNA accumulation.
In the intact mouse, inhibition of G6PD mRNA amount by dietary fat is very
rapid; a 20% decrease is observed within 4.5 h after providing a high-fat diet compared to
mice consuming a low-fat diet (5).  To test whether inhibition by fatty acids in culture
was as rapid as the inhibition by dietary fat, hepatocytes were incubated in the presence of
glucose and insulin for 48 h to induce the amount of G6PD expression prior to the
addition of arachidonic acid (Fig. 4A).  Incubation of hepatocytes for 48 h with 27 mM
glucose in the medium increased the expression of G6PD mRNA 4.1-fold, compared to
time 0.  Insulin further enhanced this accumulation 1.5-fold relative to glucose-treated
cells.  Within 2 h after the addition of arachidonic acid, the amount of G6PD mRNA was
decreased 13.8% (average of 2 experiments).  The maximum decrease of 50% in G6PD
mRNA abundance was observed by 8 h.  This decrease in mRNA was similar to the 60%
decrease observed in hepatocytes incubated with arachidonic acid coincidentally with
glucose and insulin for the entire 48 h period (Fig. 4A, 48 h lane).  The expression of
GAPDH and -actin were not affected by arachidonic acid in these cells (Fig. 4A).  The
inhibition of G6PD mRNA accumulation was also rapid when arachidonic acid was
added coincidently with glucose and insulin (Fig. 4B).  The amount of G6PD mRNA was
decreased 52% within 12 h of treatment in the absence of changes in the expression of
GAPDH and -actin (Fig. 4B).  Thus, polyunsaturated fatty acids inhibit the insulin
stimulation of G6PD mRNA accumulation when added coincidentally with insulin and
glucose, or when added to cells that were previously incubated with insulin and glucose
for 48 h.  Further, the kinetics of inhibition by polyunsaturated fatty acids in hepatocytes




































Figure 4.  Time course of the inhibition of G6PD mRNA accumulation by arachidonic
acid.  Rat hepatocytes were isolated and cultured as described.  (A) Twenty four hours
later, the medium was replaced with one containing 0.1 µM insulin, 27 mM glucose and
Matrigel (0.3 mg/ml) .  The medium was replaced every 24 h to one of the same
composition but without Matrigel.  Arachidonic acid (250 µM) was added after 48 h of
incubation with hormones.  RNA was isolated at the indicated times (2-24 h) after the
addition of fatty acid.  The 48 h lane represents RNA isolated from hepatocytes in which
arachidonic acid was added with glucose and insulin after 24 h in culture.  In addition,
cells prior to treatment (control), cells incubated with glucose alone for 48 h, and cells
incubated with glucose plus insulin for 48 h were harvested and total RNA was isolated.
Northern analysis was performed as described and results were quantified using
ImageQuaNT.  The signal for -actin was enhanced 4 times over the signals for G6PD
and GAPDH.  Similar results were obtained in two independent experiments.  (B)
Twenty four hours after hepatocyte isolation, the medium was replaced with one
containing 0.1 µM insulin, 27 mM glucose, 250 µM arachidonic acid, and Matrigel (0.3
mg/ml) . The medium was replaced every 12 h to one of the same composition but
without Matrigel.  At the indicated times, RNA was isolated and G6PD mRNA was
measured by RNase protection assay as described.  GAPDH and -actin were measured
by Northern analysis.  Quantitation was done using ImageQuaNT and the results are
expressed in relative amounts where the amount of the specific mRNA in cells incubated
without fatty acid was set to 100 (0 h).  The data are representative of two separate
experiments with similar results.
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G6PD is regulated at a posttranscriptional step in the nucleus of rat hepatocytes
We next tested if fatty acids regulated G6PD expression by a posttranscriptional
mechanism.  Nuclei were isolated from hepatocytes and transcriptional activity of the
G6PD gene was measured using nuclear run-on assays.  Transcriptional activity of the
G6PD gene was low in rat hepatocytes and little or no change was observed due to either
glucose and insulin or arachidonic acid (Fig. 5A).  The apparent increase in G6PD
transcription due to glucose and insulin shown in Fig. 5A was only observed in this
experiment.  In multiple experiments, transcriptional activity of the G6PD gene was not
significantly increased by glucose and insulin (Fig. 5B).  In the same preparation of cells,
the abundance of G6PD mRNA was increased 5-fold by glucose and insulin, whereas
arachidonic acid attenuated this increase by 47% (Fig. 5B).  Expression of the -actin
gene was not regulated by any of the treatments (Figs. 5A & 5B), thus, the transcriptional
activity of the other genes was expressed relative to transcription of the -actin gene.
Transcriptional activity of the GAPDH gene was increased 3-fold by glucose and insulin,
consistent with the change in accumulation of GAPDH mRNA.  Although PEPCK
transcriptional activity was low in the absence of transcriptional activators such as cAMP,
PEPCK transcription was still decreased 31 to 94% in hepatocytes incubated with glucose
and insulin.  Arachidonic acid did not change the transcriptional activity of the PEPCK
gene and had only a minor effect on transcription of the GAPDH gene which was not
reflected by a change in its mRNA.  In one experiment (shown), glucose and insulin
caused a two-fold increase in G6PD transcription, this was not consistently observed.
Thus, we conclude that transcription of the G6PD gene is not regulated by
polyunsaturated fatty acids.
Posttranscriptional regulation of G6PD by diet in the intact mouse and rat
involves changes in pre-mRNA accumulation in the nucleus.  We tested if arachidonic
acid inhibited G6PD expression in rat hepatocytes by changing the amount of pre-mRNA
for G6PD in the nucleus or by changing the amount of mRNA for G6PD in the
cytoplasm. Nuclear RNA was purified from hepatocytes treated with glucose and insulin
with or without arachidonic acid.  G6PD pre-mRNA was measured using the
ribonuclease protection assay as previously described.  Hybridization of each probe in the
assay with nuclear RNA resulted in two protected fragments corresponding to the full-
length protected fragment and the exon-only protected fragment (Fig. 6A).  Incubation of
the hepatocytes with glucose and insulin for 48 h resulted in a 3- to 4-fold increase in pre-
mRNA for G6PD.  This increase was observed with both the exon 9-intron 9 and intron
3-exon 4 probes.  Inhibition of G6PD pre-mRNA accumulation by arachidonic acid was




No Addition Glucose+Insulin Glucose+Insulin+20:4
G6PD 0.35  0.2 0.55  0.1 0.51  0.2
GAPDH 1.74  0.5 5.65  0.6 3.23  0.1
PEPCK 0.91  0.2 0.33  0.1 0.45  0.1
mRNA
Fold increase % Decrease
G6PD 5.0  1.0 47.0  1.0
GAPDH 2.5  0.07 9.0  3.2
-Actin 1.1  0.08 4.0  0.05
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Figure 5.  G6PD is regulated at a posttranscriptional step in rat hepatocytes.  (A)
Hepatocytes were isolated and maintained in culture as described in the legend to Fig. 3B.
Nuclei were isolated from 16 plates per treatment and nuclear run-on assays were
performed as described in Materials and Methods.  Lane 1 represents nuclei isolated from
hepatocytes at 24 h after isolation of the cells.  Lanes 2 and 3 represent the results from
nuclei isolated after 48 h of incubation with 27 mM glucose and 0.1 µM insulin (lane 2),
or 27 mM glucose, 0.1 µM insulin and 250 µM arachidonic acid (lane 3).  The amount of
hybridization of the transcripts to the DNA probes was quantified using ImageQuaNT.
Part A is a representative blot.  (B)  Quantitative results of 3 independent experiments
comparing transcriptional activity with mRNA abundance (n=2 plates per treatment per
experiment) within the same hepatocyte population.  Transcriptional activity of the
G6PD, GAPDH and PEPCK genes are expressed relative to the transcriptional activity of
the -actin gene, which was not regulated by these treatments.  Fold increase is the
amount of mRNA in hepatocytes treated with glucose and insulin divided by the amount
of mRNA in hepatocytes prior to these treatments.  The % decrease is the amount of
mRNA in hepatocytes treated with arachidonic acid divided by the amount of mRNA in
hepatocytes that were not incubated with arachidonic acid X 100.
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increase in signal intensity observed in protected fragments representing pre-mRNA
without the intron versus pre-mRNA with the intron may reflect either the detection of
cytoplasmic RNA co-purifying with the nuclei.  Using more highly purified nuclei, the
difference in these signals decreased (data not shown).  Both pre-mRNA and mature
mRNAwas decreased by arachidonic acid to a similar extent suggesting that regulation
occurs early in the nuclear processing pathway, perhaps, prior to splicing.
To determine whether changes in the pre-mRNA pool could account for the
changes in mRNA for G6PD, total RNA was prepared from the same hepatocytes and the
amount of G6PD mRNA measured using the ribonuclease protection assay (Fig. 6A).
Total RNA is primarily cytoplasmic RNA (9).  The amount of mature G6PD mRNA was
increased 3- to 4-fold by incubation with glucose and insulin, and the inhibition of G6PD
mRNA amount was 50% or more (Fig. 6B).  Thus changes in the amount of pre-mRNA
for G6PD due to insulin, glucose or arachidonic acid can account for all of the change in
G6PD mature mRNA.
Effect of monounsaturated versus polyunsaturated fatty acids on G6PD expression
Two characteristics of the inhibition of gene expression by fatty acids are that 1)
only polyunsaturated fatty acids of the n-6 and n-3 families of fatty acids are inhibitors,
and 2) the inhibition is not a consequence of toxic actions such as an increase in peroxide
formation.  We tested whether the inhibition of G6PD expression by fatty acids fulfilled
these two criteria.  Hepatocytes were incubated with glucose and insulin or glucose,
insulin and various fatty acids for 48 h.  RNA was isolated from nuclei and cells and the
amount of pre-mRNA for G6PD was measured using the ribonuclease protection assay
(Fig. 7A).  Arachidonate (n-6) and eicosapentaenoate (n-3) inhibited G6PD pre-mRNA
amount by 88% and 57%, respectively.  In contrast oleate (n-9 and one double bond) had
little or no effect.  A 45% inhibition was observed with linolenate and linolenate, the
metabolic precursors of arachidonate and eicosapentaenoate, respectively.  The lower
potency of these 18 carbon fatty acids as inhibitors was not unexpected.  Previous work
has shown that conversion of -linoleate to arachidonate is attenuated in primary
hepatocyte cultures (34).  Thus, inhibition of G6PD expression at a nuclear
posttranscriptional step is specific for long chain polyunsaturated fatty acids of the n-3
and n-6 classes.
Long chain polyunsaturated fatty acids can be subject to oxidation within cells
releasing toxic peroxides into the medium (35).  Thus we determined if the inhibition of
G6PD expression was due to a specific action of long chain polyunsaturated fatty acids or




Protected Fragment Fold-increase due to
glucose and insulin
 % inhibition due to 20:4
Intron 3- Exon 4 3.5  0.3 58  5.7
Exon 4 3.2  0.6 57  6.8
Exon 9- Intron 9 5.6  1.5 62  6.4
Exon 9 3.7  0.8 60  7.3
Total RNA




Exon 4 3.1  0.2 51  2.5
Exon 9 3.6  0.3 52  2.8
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Figure 6.  Posttranscriptional regulation of G6PD by arachidonic acid occurs in the
nucleus.  Hepatocytes were isolated and incubated with 27 mM glucose, 0.1 µM insulin
with or without 250 µM arachidonic acid (20:4) as described in Fig. 5.  The lane
indicating the absence of these additions represents RNA from cells prior to the addition
of these treatments (time 0; 24 h after hepatocyte isolation).  After 48 h of treatment,
nuclear RNA was isolated from 17 plates per treatment as described in Materials and
Methods.  Total RNA was isolated from 2 plates per treatment within the same
experiment.  G6PD mRNA in nuclear and total RNA was analyzed using a ribonuclease
protection assay.  (A) Representative experiment.  U= Undigested probe, D= RNase
digested probe.  (B) Quantitative results of 4 independent experiments (mean  SE).
Hybridization to the G6PD probes was quantified using ImageQuaNT analysis.  Fold
increase is the amount of mRNA in hepatocytes treated with glucose and insulin divided
by the amount of mRNA in hepatocytes prior to these treatments.  The % decrease is the
amount of mRNA in hepatocytes treated with arachidonic acid divided by the amount of
mRNA in hepatocytes that were not incubated with arachidonic acid X 100.
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measurement of TBA-reactive substances in the medium of the hepatocytes.  TBA-
reactive materials provide an estimate of malondialdehyde levels in the culture medium, a
primary product of peroxidation of polyunsaturated fatty acids.  The amount of TBA
reactive material was 1.44 nmol and 2.1 nmol/plate after 24 and 48 h of incubation in the
absence of fatty acids.  Regardless of the presence or the degree of unsaturation of the
fatty acid, little or no change in the amount of TBA reactive substances was observed in
the medium of the hepatocytes (range of 1.24-1.75 nmol/plate at 24 h and 1.09-1.87
nmol/plate at 48 h).  These results coupled with the lack of change in the expression of
GAPDH and -actin (Fig. 7B) indicate that the effects of long chain polyunsaturated fatty
acids on G6PD expression are not due to a generalized toxicity within the cells.
Discussion
G6PD activity and mRNA accumulation undergo large changes with
starvation/refeeding and during consumption of a high fat diet versus a low fat diet in rats
and mice (5,36).  Transcription rate of the gene does not change under these conditions
(5; Fig. 2A) and thus, regulation is posttranscriptional.  Further, this regulation occurs in
the nucleus at an early step, perhaps prior to processing events (9; Fig. 2B).  In the present
report we present several lines of evidence that fatty acids directly mediate the effect
ofdietay fat on the expression of G6PD.  First, long chain polyunsaturated fatty acids
inhibit the expression of G6PD in primary hepatocyte cultures at the same
posttranscriptional step observed with dietary fat in the intact animal.  In this regard,
G6PD expression was inhibited by arachidonic acid by decreases in the amount of pre-
mRNA for G6PD in the nucleus in the absence of transcriptional regulation of the G6PD
gene.  Second, the inhibition of G6PD expression by arachidonic acid in hepatocyte
cultures occurs rapidly.  A decrease in G6PD mRNA was detected as early as 2 h after the
addition of fatty acid and the decrease was maximal by 8 h, identical to the time course of
the decrease of G6PD mRNA observed with the intact animal (5).  Last, the specificity of
the effect of fatty acids on G6PD expression is the same as that observed in the intact
animal.  For example, polyunsaturated fatty acids but not monounsaturated fatty acids
inhibit G6PD in intact animals and in primary rat hepatocyte cultures (6,8; Fig. 7).
Our observations with respect to posttranscriptional regulation by fatty acids are
very similar to the observations with respect to transcriptional regulation by fatty acids.
Transcriptional activities of the genes for fatty acid synthase, S14, and pyruvate kinase
are inhibited by polyunsaturated fatty acids in intact animals or in hepatocytes in
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Figure 7.  Effects of polyunsaturated fatty acids and monounsaturated fatty acids on
inhibition of G6PD pre-mRNA accumulation.  (A)  Hepatocytes were isolated and
incubated in Williams’ Medium E as described in Materials and Methods.  Twenty four
hours after plates the hepatocytes, the medium was replaced with one containing 0.1 µM
insulin and 27 mM glucose with or without 250 µM fatty acids as indicated in the figure.
After 48 h in culture with the indicated treatments, nuclear RNA was isolated from 12
plates/treatment.  G6PD RNA in nuclear RNA was analyzed using the ribonuclease
protection assay.  U= Undigested probe; D= RNase digested probe.  (B) Hepatocytes were
isolated and maintained as described in part (A).  Messenger RNA for GAPDH and -
actin was measured by Northern analysis.
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primary culture (10,14,15).  The differential effect of polyunsaturated fatty acids versus
monounsaturated fatty acids is observed for these genes.  These similarities between the
transcriptional and posttranscriptional regulation by polyunsaturated fatty acids suggests
that a common fatty acid metabolite is involved in both modes of regulation.
Glucose and insulin increase G6PD expression 5- to 7-fold in the hepatocytes.
This change is similar to the increase in G6PD mRNA and pre-mRNA abundance that is
observed in mice during their typical feeding cycle (9).  In mice consuming a high-
carbohydrate, low-fat diet ad libitum, the amounts of G6PD mRNA and pre-mRNA
increase 7-fold from a low level prior to the onset of the dark or feeding cycle, to the
highest level observed 8 h into the dark cycle (9).  Thus, factors needed for the positive
regulation of G6PD expression appear to be present in the hepatocyte system.
Arachidonic acid inhibited G6PD enzyme activity and mRNA accumulation by 50-60%
due to arachidonic acid.  These changes are somewhat smaller than the 80% decreases
observed in the intact animal.  The attenuated effect of fatty acids may reflect that the
effect of dietary fat is not exclusively due to the fatty acids in the diet but may also
involve hormonal regulation.  Alternatively, this may reflect an absence of some of the
regulatory factors in primary hepatocyte cultures needed to observe the maximal effect.
The inhibition of G6PD expression by arachidonic acid was only observed in cells
treated with both glucose and insulin.  Arachidonic acid does not decrease the amount of
G6PD mRNA in hepatocytes treated only with glucose.  The simplest interpretation of
these observations is that polyunsaturated fatty acids inhibit signal transduction by
insulin.  As insulin is also thought to stimulate glucose metabolism in hepatocytes and
generation of the glucose-signal (37), the step in signal transduction inhibited by
arachidonic acid must be downstream of the step involved in glucose utilization.
Alternatively, separate signalling pathways may be involved in insulin stimulation of
glucose metabolism and insulin stimulation of G6PD expression.  Formal proof of this
hypothesis will require the identification of the specific signals involved in regulation by
insulin and fatty acids.  It is not clear if all genes inhibited by arachidonic acid will share
a similar signal transduction pathway.  In this regard, the activity of fatty acid synthase is
inhibited by polyunsaturated fat in diabetic rats (38) suggesting a mechanism independent
of insulin.  Inhibition of fatty acid synthase by fatty acids with and without insulin has not
been tested in primary hepatocyte cultures.
Examples of nutrient regulation at posttranscriptional steps indicate that
cytoplasmic mRNA stability is the primary process involved.  For example, excess
cellular iron leads to a decrease in stability of the transferrin receptor mRNA which is
mediated by the binding of an iron regulatory protein to the iron response element in the
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3’-UTR of the transferrin receptor mRNA (39,40).  Glucose increases the stability of the
fatty acid synthase mRNA.  Incubating HepG2 cells with increasing concentrations of
glucose stimulates a 5-fold increase in fatty acid synthase mRNA in the absence of
transcriptional regulation (41).  The mechanism for this stability appears to involve a
differential partitioning of the cytoplasmic mRNA between a translated pool protected
from degradation and a decay compartment (42).  Fatty acids also act
posttranscripitionally by decreasing the stability of glut-4 (43) and stearoyl-CoA
desaturase I (44) mRNAs in the cytoplasm of 3T3-L1 adipocytes.  In contrast, the
posttranscriptional mechanism involved in the regulation of G6PD by nutrients is quite
different in that it occurs in the nucleus and involves the pre-mRNA (Fig. 6B).
Regulation of pre-mRNA in the nucleus could result from a change in the rate of
processing of the pre-mRNA, stability of pre-mRNA in the nucleus or a block in transport
of mRNA from the nucleus to the cytoplasm.  Posttranscriptional regulation in the
nucleus has been reported for several genes.  The putative lipogenic protein, S14, is
regulated partly by a nuclear posttranscriptional mechanism which involves enhanced
splicing of S14 pre-mRNA during consumption of a high-carbohydrate diet or after
insulin administration (12,13).  Fibronectin and liver/kidney/bone alkaline phosphatase
genes are both regulated by accumulation of the pre-mRNA for these genes in the
nucleus.  The fibronectin gene is regulated by dexamethasone (45) or by transformation
of TE-85 cells with Ha-ras (46), whereas alkaline phosphatase is regulated in a tissue-
specific manner (47).  Changes in expression of fibronectin and the alkaline phosphatase
genes are not mediated by changes in transcription, splicing or polyadenylation.  In both
of these cases, nuclear stability of the pre-mRNA is the postulated mechanism, although
this has not been tested experimentally.
Regulation of G6PD pre-mRNA accumulation is most likely occurring early after
transcription of the gene, perhaps prior to processing.  Accumulation of G6PD mRNA in
the cytoplasm due to consumption of a high-carbohydrate diet occurs shortly after an
increase in pre-mRNA is observed in the nucleus thereby ruling out nuclear-cytoplasmic
transport as a potential regulatory mechanism (9).  Whether regulated by diet or nutrients
in cultured hepatocytes, the similarity in the rate of change of pre-mRNAs both with and
without introns suggests that the efficiency of splicing is also not a regulated step.
Regulation could, however, involve any of the other processing reactions occurring
within the nucleus such as capping or polyadenylation.  Deadenylation and decapping of
pre-mRNA can function as regulatory mechanism in the nucleus (48) but are most often
associated with the presence of nonsense codons (49).  In previous work (9) we detected a
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selective disappearance of the 3’-most portion of G6PD pre-mRNA as a result of dietary
manipulation.
We hypothesize that nuclear posttranscriptional regulation of G6PD occurs early
after transcription by differential partitioning of the pre-mRNA into various
compartments in the nucleus.  This idea is not without precedent.  For example,
processing of pre-RNAs is thought to occur in close association with the nuclear matrix
(50-52).  Further, this type of compartmentalization has been suggested for the regulation
of the alkaline phosphatase gene by retinoic acid (53).  Stabilization of the nascent
alkaline phosphatase mRNA by retinoic acid is hypothesized to occur by enhanced
processing of the pre-mRNA in the nuclear matrix compartment thereby facilitating
movement through the nucleus to the cytoplasm.  Preliminary evidence from our
laboratory suggests that this is also the case for G6PD (Amir-Ahmady and Salati,
unpublished results).  The amount of G6PD pre-mRNA on the nuclear matrix is increased
in livers of fed mice relative to livers of mice that have been starved.  Perhaps a protein is
induced during high-carbohydrate feeding which facilitates the movement of the pre-
mRNA through the nuclear processing reactions, thus protecting it from degradation.  In
the starved animal or animal fed a high-fat diet, the activity or amount of this protein may
be decreased and thus association with the nuclear matrix would not occur.  Pre-mRNA
not associated with the nuclear matrix would be more susceptible to degradation by
RNases in the nucleus.
In summary, regulation of G6PD by polyunsaturated fatty acids in primary rat
hepatocytes is mediated by a nuclear posttranscriptional mechanism.  This mechanism of
regulation by fatty acids has not previously been described for other genes.  However,
nuclear posttranscriptional regulation may be a common mechanism for all lipogenic
genes.  The data with carbohydrate regulation of S14 (12) suggests that such a regulatory
mechanism occurs in a gene that also undergoes transcriptional changes to the same
stimulus.  G6PD provides an ideal model to examine this form of regulation because of
the absence of transcriptional changes which would confound the interpretation of nuclear
events.  Experiments are currently in progress aimed at determining the cis-acting
elements within the G6PD pre-mRNA sequence involved in regulation by
polyunsaturated fat using this cell culture system.
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CHAPTER 3.  LOCALIZATION OF A FATTY ACID RESPONSE ELEMENT
WITHIN THE G6PD MATURE SEQUENCE
Introduction
Dietary polyunsaturated fatty acids (PUFA) have been shown to decrease the
expression of a number of genes involved in lipid and carbohydrate metabolism such as
fatty acid synthase (FAS) (1), liver-type pyruvate kinase (L-PK) (2), spot 14 (S14) (1),
stearoyl-CoA desaturase I (SCD1) (3) and glucose-6-phosphate dehydrogenase (G6PD)
(4,5).  G6PD is regulated very differently by PUFA compared to the other lipogenic
enzymes.  Addition of PUFA to a high-carbohydrate diet results in a decrease in the
amount of G6PD precursor mRNA (pre-mRNA) in the nucleus, in the absence of changes
in the rate of transcription of the gene (6,7).  In addition, the changes in the amount of
G6PD pre-mRNA in the nucleus parallel the changes in the amount of mature G6PD
mRNA in the cytoplasm, which suggests that the nucleus is the primary site of regulation.
The amount of G6PD pre-mRNA is regulated early in the processing pathway, without
apparent regulation of splicing, nucleocytoplasmic transport, or changes in stability of the
pre-mRNA (6).  In contrast, other PUFA-regulated enzymes undergo large transcriptional
changes in response to diet or hormones with only small components of
posttranscriptional regulation in some genes (8-10).  G6PD provides an ideal model to
study the posttranscriptional regulation because of the absence of transcriptional
regulation which would otherwise confound the interpretation of intranuclear events.
One possibility for the exclusive posttranscriptional regulation of G6PD is that G6PD
plays multiple roles in the cell in addition to its role in lipogenesis.  Posttranscriptional
regulation would allow increased expression of G6PD in liver when the needs for
lipogenesis are great but uniform expression in all cells for other roles such as cellular
detoxification and nucleotide biosynthesis.  On the other hand, fat biosynthesis is the
main function of many of the other lipogenic genes.
Nuclear posttranscriptional regulation can occur by many mechanisms including
capping, polyadenylation, splicing, nonsense-mediated decay, nuclear pre-mRNA stability
or regulated processing.  The role of the nuclear matrix in regulated processing is
becoming increasingly evident.  For example, the nuclear matrix has been hypothesized to
function as an anchor for actively transcribed chromatin and to direct newly synthesized
RNA into the processing pathway for processing and transport to the cytoplasm (11-14).
Thus, the nuclear matrix can potentially be the site of posttranscriptional regulation of
G6PD.  Preliminary data from our laboratory suggest that posttranscriptional regulation of
G6PD gene expression by diet occurs by changes in the amount of precursor mRNA that
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enters the processing pathway (Amir-Ahmady and Salati, unpublished results).  Our
hypothesis is that this regulation involves the binding of trans-acting regulatory proteins
in the nucleus to cis-acting elements within the G6PD pre-mRNA to mediate either
stability or degradation of the mRNA.  The nature of the RNA element in G6PD pre-
mRNA involved in this regulation is of interest to this laboratory.
Only a few cis-acting RNA elements involved in nuclear RNA stability have been
identified.  One such element is the premature termination codon which targets the RNA
for degradation either prior to or coincident with its export from the nucleus (15).  These
elements arise by mutation (16).  One could envision a mechanism whereby a slowly-
spliced intron could result in an apparent premature termination codon but this has not
been demonstrated experimentally.  RNA elements have also been identified within the
coding region of pre-mRNA which enhance splicing (14).  A direct relationship between
these elements and nuclear RNA stability has not been studied.
The goal of these studies is to localize a PUFA response element in the G6PD pre-
mRNA.  Since all of the regulation of G6PD by PUFA is occurring in the nucleus, any
region of the primary transcript can be subject to regulation.  The G6PD primary
transcript is 18 kb necessitating the use of reporter constructs containing subsets of these
sequences.  Chimeric constructs containing portions of the 18 kb G6PD gene, either
exonic sequences or 3’-UTR sequences, were transiently transfected into primary rat
hepatocytes. Arachidonic acid inhibits G6PD expression both quantitatively and
qualitatively in primary hepatocyte cultures at the same intracellular step as dietary
polyunsaturated fat in the intact animal (17).  Thus, the primary rat hepatocytes provide
an ideal model system in which to identify a PUFA response element for G6PD.
Materials and methods
Materials.  Arachidonic acid (Nu-Chek Prep), collagenase H (EC 3.4.99.5,
Boehringer Mannheim), insulin (Eli Lilly Research Laboratories), Matrigel (Collaborative
Biomedical Research), Percoll (Sigma), pBluescriptKS+ (Stratagene), pGL3-Basic
(Promega), pCMV (Clontech), RNasin (5 Prime-3 Prime, Inc.), EndoFree Plasmid
Purification kit (Qiagen) and Galacto-Light kit (Tropix) were obtained from the
indicated sources.  Williams’ medium E, newborn calf serum, Klenow, RNase-free
DNase I and lipofectin were from Gibco-BRL.  RPA II kit and CAT Direct kit were
purchased from Ambion.  Bovine serum albumin fraction V (fatty acid-free) and -
[32P]UTP, 3000 Ci/mmol were from ICN Biochemicals.  Other chemicals were from
Fisher Biotech or of the highest purity commercially available.  Rats were purchased from
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Harlan Laboratories (Indianapolis, IN).  Standard chow diet was Harlan Teklad.  Rat
genomic DNA was obtained from Clontech.
Animal care and cell culture.  Male Sprague-Dawley rats (approximately 200 g)
fed on a standard chow diet were used for all experiments.  Rats were starved for 48 h
prior to use as hepatocyte donors.  The cell culture procedure is as described (17, Chapter
2).
Plasmid construction.  The pcDNA construct was made using pGL3-Basic
(Promega) as the parent plasmid and the 3’-UTR constructs were made using pCMV
(Clontech) as the parent plasmid.  Fig. 1A shows the parent vectors and 1B shows the test
constructs and lists the features of each one.  The structure of all the constructs described
below was verified by restriction digestion and sequencing across splice junctions.
pcDNA construct:  pGEM-4Z was obtained from M. Zollo (18) and contains the
mouse G6PD cDNA, lacking 11 nt 3’ of the transcription start site, inserted into the
EcoRI site of the pGEM vector.  For subcloning purposes, the orientation of the cDNA to
the plasmid vector was reversed so that the multiple cloning site was now located 5’ of
the G6PD sequences.  This was done by digestion with EcoRI to remove the G6PD
cDNA sequence followed by religation into the plasmid.  The correct orientation of insert
to plasmid was determined by restriction enzyme digestion.  Next, an additional 25 nt 5’
of the G6PD cDNA was added from plasmid p123 so as to include the transcription start
site which was missing in pGEM-4Z.  This plasmid, p123, contains 132 nt of G6PD 5’-
flanking sequences and G6PD exons 1, 2 and 3 cloned into pBluescriptKS+ (19).  There
is a unique BstEII restriction site in exon 3 and a HindIII restriction site in the G6PD 5’-
flanking region 25 nt upstream of the transcription start site.  Plasmid p123 was digested
with HindIII and BstEII.  A 201 bp fragment was isolated from this digest.  pGEM-4Z
with G6PD in the new orientation was also cut with HindIII and BstEII.  A 2.3 kb band
was isolated and directional cloning was done resulting in a plasmid containing 25 nt of
5’-flanking DNA, the entire mouse G6PD cDNA and the pGEM backbone.
Next all of the G6PD sequences were subcloned into an expression vector, pGL3-
Basic.  The pGL3-Basic vector contains a high copy number prokaryotic origin of
replication for maintenance in E. coli, an ampicillan resistance gene for selection, a
filamentous phage origin of replication for single stranded DNA production, the SV40
late poly(A) signal, a synthetic poly(A) and transcriptional pause site for background
reduction, and the firefly luciferase cDNA (Fig. 1A).  In addition, pGL3-Basic lacks
eukaryotic promoter and enhancer sequences allowing maximum flexibility in cloning
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Figure 1.  A)  Parent vectors for designing chimeric constructs, pGL3-Basic and pCMV.
MSC= multiple cloning site.  SD/SA= splice donor/splice acceptor.  B)  cDNA and 3’-
UTR constructs.  The pcDNA construct contains the CMV promoter inserted in the
polylinker of the pGL3-Basic vector and the full-length G6PD cDNA inserted in place of
luciferase.  The SV40 late polyadenylation signal has been deleted since the G6PD DNA
contains the native polyadenylation signal.  Three different constructs were designed to
detect cis-acting elements in the 3’-UTR, designated 3’-UTR-1, 3’-UTR-2 and 3’-UTR-3.
G6PD sequences were added within the context of the -galactosidase gene of the
pCMV	vector.  K= KpnI, Sm= SmaI, X= XhoI, H= HindIII, B= BamHI, E= EcoRI,
Bpu= Bpu1102I.  A line through the names of restriction enzymes indicates those sites
that were destroyed during the cloning.
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were removed from the pGL3-Basic plasmid using HindIII and BamHI restriction
enzymes and replaced with a HindIII-EcoRI fragment of G6PD cDNA plus the additional
25 nt of 5’-flanking sequences from the pGEM-4Z to make pcDNA (Fig. 1B).  The
BamHI and EcoRI sites were filled in with Klenow to create blunt-ends.  Thus, these sites
have been destroyed in the cloning process.  The G6PD DNA contains the native
polyadenylation signal in exon 13, thus the SV40 late polyadenylation signal was deleted
to prevent inclusion of vector sequences in the RNA due to utilization of the vector
polyadenylation signal.
Finally, the cytomegalovirus (CMV) promoter was added to the pcDNA construct.
The 639 bp band of the CMV promoter was excised from pCMV (Fig. 1A) using XhoI
and EcoRI.  The EcoRI site was filled in with Klenow to create a blunt end.  This
fragment was subcloned into the 5.5 kb pcDNA construct which was cut with XhoI and
SmaI (blunt).  The final pcDNA construct contains 12 nt of untranscribed, the entire 66 nt
of 5’-UTR and 622 nt of 3’-UTR sequences for the G6PD gene and mRNA.  The
approximate size of this construct is 6 kb.
pCMV-GL3-Gal:  This is a control plasmid to ensure that the vector and promoter
sequences of the pcDNA construct (made using pGL3-Basic as the parent plasmid) are
not regulated by the experimental treatments.  It contains the pGL3-Basic vector
backbone, the CMV promoter, and the -galactosidase gene in place of G6PD.
Luciferase was removed from pGL3-Basic by restriction digestion with NarI and SalI.
The DNA from a 2929 bp band was purified.  Next, the CMV promoter and -
galactosidase sequence was removed from the pCMV parent vector by restriction
digestion with NarI and SalI.  The DNA from a 4671 bp band was purified from this
digest.  The 2929 bp band and 4671 bp band were ligated together to make pCMV-GL3-
Gal.
3’-UTR constructs:  Three different constructs were used to detect cis-acting
elements in the 3’-UTR (Fig. 1B).  G6PD sequences were added within the context of the
-galactosidase gene of pCMV.  pCMV is the control plasmid to ensure that the vector
and promoter sequences of these 3’-UTR constructs are not regulated by experimental
treatments.
3’-UTR-1 construct:  3’-UTR-1 was constructed by PCR amplification of mouse
genomic DNA.  The amplified sequence included exon 12 (starting at position 1454 in
the mouse cDNA sequence), intron 12, exon 13, and 3’-flanking DNA 160 bp from the
polyadenylation signal using primer 1, 5’-GCGCGGCTGAGAGCTGCTGCACAAG
ATTGATCGAG-3’ and primer 2, 5’-GCGCAAAGCTTTGGACTG TAGCTTC-3’.  The
single underlined sequence is a Bpu1102I restriction site for subcloning purposes
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followed by G6PD exon 12 specific sequences.  The double underlined sequence is a
HindIII restriction site for subcloning purposes followed by G6PD exon 13 specific
sequences. The 3’-UTR of -galactosidase was excised from pCMV (Fig. 1A) by
digestion with HindIII and Bpu1102I.  This was replaced with the 1091 bp PCR amplified
G6PD sequence containing the same restriction sites which resulted in a 7.7 kb plasmid.
3’-UTR-2 construct:  The SV40 intron is known to enhance expression of
transgenes (20).  However, the presence of these sequences may interfere with the mode
of regulation of G6PD.  Therefore, the SV40 intron and splice donor/splice acceptor site
were removed from 3’UTR-1 by restriction digestion with SmaI and XhoI followed by
Klenow treatment and religation to make 3’-UTR-2.  This construct retains all the G6PD
sequences of 3’-UTR-1.
3’-UTR-3 construct:  G6PD exon 12 and intron 12 were removed from 3’-UTR-1
by restriction digestion with Bpu1102I and KpnI followed by Klenow treatment and
religation to make 3’-UTR-3.  Thus, this construct contains G6PD exon 13, 3’-flanking
DNA and the SV40 intron.
Transient transfection of primary hepatocytes.  Plasmid DNA for all
transfections was purified using the Qiagen EndoFree plasmid purification kit.
Endotoxins have been shown to influence DNA transfection efficiency in cultured cells
(21).  In our hands, endotoxin free purified DNA results in higher transfection efficiency
than standard purification procedures (data not shown).  Transfection of primary
hepatocytes was performed using liposome-mediated uptake (22).  All plasticware that
came in contact with the transfection reagents was made of polystyrene.  The formation of
liposome/DNA complexes was carried out by mixing 5 µg of test plasmid DNA and 1 µg
of control pRSV-CAT in 1 ml media/60 mm plate (Solution A) and 40 µg of Lipofectin
reagent in 1 ml media/60 mm plate (Solution B).  This resulted in a 1:6.7 ratio of DNA to
liposomes.  Solution B was incubated at room temperature for 30-45 min.  Solution A
was added to Solution B and mixed by gentle inversion and this incubation continued for
10-15 min at room temperature.  The DNA/liposome complex was added directly to the
hepatocytes directly after the 4 h attachment period.  The cells were incubated for 14 h in
the presence of the DNA/liposome complexes.  At that time, the medium containing
liposome/DNA complex was removed and replaced with media containing the
experimental treatments and Matrigel overlay as previously described (23).  Cells were
incubated with these treatments for the times indicated in the figure legends.
Ribonuclease protection assay.  Four G6PD specific probes were designed for
use in the ribonuclease protection assay (Fig. 2A).  The rat G6PD exon 13 probe was
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Figure 2.  Probe design for ribonuclease protection assay.  A)  Mouse and rat probes.  The
diagram schematically depicts the G6PD precursor mRNA.  For simplicity only 4 of the
13 exons of the G6PD gene are shown.  A probe for exon 13 of mouse mRNA hybridizes
to a 314 nt fragment that is located 13 nt 5’ of the poly(A) tail.  Three probes were
designed for the rat mRNA.  The intron 3-exon 4 protects a 204 nt fragment of pre-
mRNA containing intron 3.  In addition, this probe recognizes 97 nt of processed
transcripts (dashed line) that have undergone splicing of intron 3.  The exon 9-intron 9
probe protects a 286 nt fragment of the transcript containing intron 9 and nuclear mRNA
without intron 9 (165 nt fragment, dashed line).  The rat exon 13 probe hybridizes to a
232 nt fragment that is located 89 nt 5’ of the poly (A) tail.  B)  The 3’-end of exon 13 is
different in mice and rats.  R= Rat G6PD exon 13 sequence.  M= Mouse G6PD exon 13
sequence.  Solid arrows represent starting bases for forward and reverse primers used for
amplifying the sequence of the rat exon 13 probe.  Open arrows represent starting bases
for forward and reverse primers used for amplifying the sequence of the mouse exon 13
probe.  Bases which are in bold and underlined are those that are different in the rat
versus mouse sequence.
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derived from PCR amplification of genomic rat DNA using primer 3, 5’-CGGAATTCT
GGAGGGACAATGACCAAACC-3’ and primer 4, 5’-CGCGGATCCGGTTGGAT
GAGGCTGACTATGGAC-3’.  The 5’-end of primer 3 contained an EcoRI restriction
site (underlined sequence) for subcloning purposes followed by sequence specific for rat
G6PD exon 13.  The 5’-end of primer 4 contained a BamHI restriction site (double
underlined) for subcloning purposes followed by sequence specific for rat G6PD exon 13.
The PCR amplified product was subcloned into the EcoRI and BamHI sites of
pBluescriptKS+ and linearized with HindIII for use in in vitro transcription.  This probe
protects a 232 nt fragment when hybridized to rat RNA in ribonuclease protection assays.
The mouse exon 13 probe was described by Hodge and Salati (6).  The rat intron
3-exon 4 probe and exon 9-intron 9 probe were described in Chapter 2 (17).  Two other
probes were used in the ribonuclease protection assay, chloramphenicol acetyl transferase
(CAT) and -galactosidase.  These antisense probe templates were part of the CAT-
Direct kit purchased from Ambion.  The CAT probe protects a 152 nt fragment and the -
galactosidase probe protects a 300 nt fragment when hybridized to total RNA in
ribonuclease protection assays.  Synthesis of antisense RNA probes and ribonuclease
protection assays were performed exactly as described in Chapter 2 (17).
Preparation of cell extracts and -galactosidase assay.  This protocol is
specific for the -galactosidase activity experiments in Fig. 5A.  In these experiments, it
was not necessary to use 60 mm plates since we could obtain sufficient protein from 35
mm plates for this assay.  Transfected cells from 35 mm plates were rinsed two times in
1X phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO47H20, 1.4 mM KH2PO4, pH 7.4).  Lysis solution (500 
l; 100 mM potassium
phosphate, pH 7.8, 0.2% Triton X-100, 1 mM DTT) was added per 35 mm plate and
scraped into a microfuge tube.  The cells were disrupted by sonication for 15 sec at 4C.
The cell mixture was centrifuged for 2 min in a microfuge to pellet cell debris.  The
supernatant was stored at -70C.
Total protein content was determined by the method of Bradford (24).  -
galactosidase activity was measured using the Galacto-light kit and a Berthold LB953
AutoLumat luminometer.  Galacton chemiluminescent substrate (provided in kit as
100X concentrate) was diluted 100-fold with Galacto-Light Reaction Buffer Diluent
(100 mM sodium phosphate pH 8.0, 1 mM magnesium chloride) to make the working
Reaction Buffer.  Cell extracts (5-15 µg protein) were aliquoted into luminometer sample
cuvettes and Reaction Buffer (200 µl at room temperature) was added to the luminometer
cuvette.  The reactions were incubated at room temperature for 60 min.  Accelerator (300
µl) containing a ready-to-use luminescence accelerator reagent was added, the reaction
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was mixed by the force of the addition and the luminescence was counted for 5 sec.
Galacton substrate present in the reaction buffer is cleaved by the -galactosidase
enzyme.  A light emission accelerator was added in the same consistent time frame as the
Reaction Buffer was added.  Data are reported as relative light units (RLU) per µg of
protein.
Cellular fractionation.  Hepatocytes were isolated as described above.  The
subcellular fractions were isolated after 24 h of treatment with glucose and insulin by a
modification of the method of Leppard and Shenk (25).  The fractionation scheme is
shown in Fig. 3.  Cells were scraped from 65-90 plates (60 mm) into 50 ml centrifuge
tubes and centrifuged at 490 rpm (50 X g) in a JS 4.2 rotor for 5 min.  The pellet was
washed two times in 1 X PBS.  The resulting pellet was resuspended in 3 ml isotonic
buffer [10 mM Tris, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 175 g/ml
phenylmethylsulphonyl fluoride (PMSF)].  The final volume was 4 ml.  Nonidet NP-40
(200 µl of 10% solution; 0.5% final concentration) was added and the mixture was
homogenized with 12 strokes of a loose dounce pestle followed by 12 strokes with a tight
pestle.  The homogenate was incubated on ice for 5 min and then centrifuged at 2000 rpm
(800 X g) in a JS 4.2 rotor for 5 min.  The supernatant (cytoplasmic fraction) was
transferred to a fresh tube.  The nuclear pellet was resuspended in 2 ml of isotonic buffer
and centrifuged as before.  This supernatant was added to the previous cytoplasmic
fraction supernatant.  The pellet was resuspended in 2 ml isotonic buffer.  Nonidet NP-40
(100 µl of 10% solution; 0.5% final concentration) and 50 µl of 10% sodium
deoxycholate (0.25% final concentration) was added, vortexed and incubated on ice for 5
min and then pelleted as before.  The supernatant (nuclear membrane) was transferred to
a fresh tube.  The pellet was resuspended in 2 ml reticulocyte suspension buffer, RSB, (10
mM NaCl, 10 mM Tris, pH 7.5, 3 mM MgCl2, 175 g/ml PMSF) and centrifuged as
before.  The supernatant was transferred to the previous nuclear membrane fraction.  This
pellet was resuspended in 0.5 ml RSB.  DNase I (approximately 1000 Units in 5 µl) and
RNasin (5 µl; 30 U/µl) was added and the mix was incubated at room temperature for 30
min, followed by centrifugation for 10 min at 2500 rpm (1000 X g) in a JS 4.2 rotor.  The
supernatant (DNase soluble fraction) was transferred to a fresh tube.  The pellet was
resuspended in 1 ml RSB, 250 µl of 5 M NaCl (1.25 M final concentration) was added
and incubated at room temperature for 5 min.  This mixture was centrifuged as before.
The supernatant (salt soluble fraction) was transferred to a fresh tube.  The final pellet
contains the nuclear matrix.  RNA was isolated from this final pellet by the method of
Chomczynski and Sacchi (26).
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Figure 3.  Cellular fractionation scheme.  Five cellular fractions were isolated:
cytoplasmic, nuclear membrane, DNase soluble, salt soluble, and nuclear matrix.
Total RNA was isolated from each cellular fraction as described in Materials and
Methods.  NP40= Nonidet NP40; NaDOC= sodium deoxycholate.
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To isolate RNA from all other fractions (27), an equal volume of denaturing solution (8
M urea, 350 mM NaCl, 10 mM EDTA, 1% SDS, 10 mM Tris, pH 7.4) was added.
Sodium acetate (1/10 volume of a 2 M solution at pH 4.0) was added and the mixture was
vortexed.  Protein was extracted by addition of an equal volume of phenol (water
saturated) and chloroform/isoamyl alcohol (24:1; 50/50) and thoroughly mixed.  The
mixture was incubated on ice for 15 min followed by centrifugation at 4000 rpm (4500 X
g) for 20 min in a JS 4.2 rotor.  The aqueous phase was transferred to a fresh tube and the
RNA was precipitated with an equal volume of isopropanol (-20C overnight).  The RNA
was pelleted at 4000 rpm (4500 X g) in a JS 4.2 rotor for 30 min and the pellet was
washed in 75% ethanol, dissolved in DEPC-treated water and quantitated
spectrophotometrically.  The RNA was stored at -70C prior to use.  Recovery of RNA
from each fraction starting with 65 plates (60 mm) was 300-500 µg (cytoplasmic), 20-25
µg (nuclear membrane), 25-35 µg (DNase soluble), 30-100 µg (salt soluble) and 70-90 µg
(nuclear matrix).
Isolation of total RNA and Northern analysis.  Total RNA from 1-3 plates per
treatment was isolated by the method of Chomczynski and Sacchi (26).  The denatured
cell mix [3 ml solution D/1-3 plates (60 mm)] was forced through an 18 gauge syringe
two to three times to sheer genomic DNA.  Quantitation of RNA using Northern analysis
was done as previously described (7).
Lithium chloride treatment of RNA.   One problem when isolating RNA from
transiently transfected cells is that the transfected plasmid can be copurified with the
RNA.  This could lead to potential problems when using the ribonuclease protection
assay because the RNA probes will hybridize to both RNA and DNA in this assay.
Plasmid DNA contamination can be eliminated by either LiCl precipitation which
selectively precipitates the RNA (28) or DNase I digestion (29).  In the absence of either
of these treatments, we observed a significant amount of DNA contamination.  RNA was
dissolved in 0.1 X SET (10% SDS, 100 mM Tris-HCl, pH 7.5, 50 mM EDTA).  LiCl was
added to a final concentration of 2 M.  The RNA was precipitated overnight at 4C and
centrifuged at 3000 rpm for 15 min.  The pellet was washed one time with 2 M LiCl and
resuspended in DEPC-treated water.  The RNA was quantitated spectrophotometrically.
DNase I treatment of RNA.  The desired amounts of RNA samples isolated from
transiently transfected cells were aliquoted into microfuge tubes and brought up to an
equal volume in all samples with 1X NEBuffer 2 (10 mM Tris-HCl, 10 mM MgCl2, 50
mM NaCl, 1 mM DTT, pH 7.9 at 25C; New England Biolabs) in DEPC-treated water.
This was incubated with 2 U of RNase-free DNase I per 5 µg RNA for 15 min at 37C
immediately before use in a ribonuclease protection assay.  After the 15 min incubation,
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the riboprobes were added and both the RNA and probe were co-precipitated with
ethanol.  Extraction of the sample RNA from DNase I is not required since all subsequent
steps involving RNA-RNA interactions are unaffected by DNase I.  Subsequent
hybridization and RNase digestions were done as described in the Ribonuclease
Protection Assay section in Chapter 2 (17).
Results
Assays to measure transgene and endogenous gene expression
In order to test the functional activity of the G6PD test constructs, we had to
design an assay that would allow us to distinguish between the transgene (mouse G6PD
sequences) and the endogenous G6PD gene in the rat hepatocytes.  G6PD exon 13 is
significantly different between mouse and rat (Fig. 2B) and provides the basis of an assay
to distinguish between the endogenous rat gene and the transfected pcDNA transgene.
Using ribonuclease protection assays, our laboratory has shown that even a single
basepair difference in the ribonuclease protection assay probe versus the RNA sequence
to which it should hybridize results in a cleavage by RNases A/T1 and thus the
appearance of an extra band in these assays.  Differences between rat and mouse are
enough to allow the RNases A/T1 mixture to digest the rat RNA/mouse probe hybrid or
mouse RNA/rat probe hybrid into smaller fragments.  To ensure the validity of this assay,
total mouse liver RNA or rat hepatocyte RNA was hybridized with the two different
G6PD exon 13 probes, rat and mouse.  The rat exon 13 probe contains 27 differences
from the mouse sequence, 17 transitions and 10 transversions (see the underlined bases in
Fig. 2B).  This probe detects the endogenous rat gene and protects a fragment of 232 nt; it
does not protect a fragment of this size in mouse RNA (Fig. 4).  The mouse probe
contains 32 differences from the rat sequence, 21 transitions and 11 transversions (see the
underlined bases in Fig. 2B).  This probe protects a 314 nt fragment of the 3’-end of
mouse exon 13 in mouse RNA, but not in rat RNA (Fig. 4).  The second band (211 nt) in
the mouse RNA lane is due to a single nucleotide mismatch in the mouse probe.  The
mismatch occurred due to a transcription error during PCR.  This probe was corrected for
all future experiments.  Further, the difference in size between these two probes permits
their use simultaneously with a single aliquot of RNA.
Additionally, in the cDNA transfection assays, expression of pRSV-CAT was
measured using the probe designed by Ambion.  This probe protected a 152 nt fragment
of CAT mRNA.  Thus, all three probes were used with a single aliquot of RNA and the
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Figure 4.  Assay to distinguish between the transgene and endogenous G6PD mRNA.
Two probes were designed as described in Materials and Methods, exon 13-mouse and
exon 13-rat.  Each probe recognizes a region at the 3’-end of exon 13 which is
significantly different between the mouse and rat.  Total RNA was isolated from mouse
liver or rat hepatocytes.  RNA (25 µg) from each species was hybridized to both probes
and analyzed using a ribonuclease protection assay.  Digested and undigested lanes



































protected fragments resulting from these three probes were separated on a polyacrylamide
gel.  This allowed us to measure the pcDNA gene construct, the endogenous rat G6PD
gene and a control for transfection efficiency (CAT) all in one tube.  Because RSV-CAT
was a control for transfection efficiency, we first determined that CAT expression was
not regulated by arachidonic acid.  In 3 separate experiments the amount of CAT mRNA
was not changed by the addition of fatty acids to the hepatocytes (Fig. 5B).  Thus,
expression of CAT mRNA reflected the amount of DNA taken up by the hepatocytes and
expressing the amount of G6PD transgene mRNA per the amount of CAT mRNA
corrected for differences in uptake between dishes of hepatocytes.
The -galactosidase transgenes produced from the 3’-UTR constructs were
detected using a -galactosidase probe from Ambion.  This probe protected a 300 nt
fragment in ribonuclease protection assays.  The endogenous gene was detected using the
rat exon 9-intron 9 probe and protected a 165 nt fragment in total RNA and the
expression of pRSV-CAT was measured with the CAT probe from Ambion which
protected a 152 nt fragment as described above.  Thus, all three probes were measured in
a single aliquot of RNA just as for the pcDNA assay.  We chose the 24 h time point to
isolate RNA from all experiments because at this time point we observed the maximal
stimulation of endogenous G6PD expression due to glucose and insulin and the maximal
inhibition due to fatty acids (17).  In addition, the expression of the transgenes appeared
to be at steady state at this time (data not shown).  Thus a decrease in the amount of a
mRNA produced from any of these constructs in hepatocytes incubated with arachidonic
acid would indicate the presence of a putative regulatory domain.
CMV promoter is not regulated by fatty acids
The CMV promoter was used in all constructs.  In order to ensure that any
regulation observed with the transgenes was not due to regulation of the CMV promoter,
we measured the expression of pCMV- (Clontech) in hepatocytes incubated with and
without arachidonic acid.  Both -galactosidase activity and mRNA were readily
detectable in the transfected hepatocytes (Fig. 5).  Neither the activity nor the
accumulation of the mRNA were different in hepatocytes incubated with glucose and
insulin plus or minus arachidonic acid (Fig. 5A and B, experiments 1 and 2).  In the same
experiments endogenous G6PD mRNA levels were measured using the ribonuclease
protection assay with the rat exon 13 probe in experiment 1 and the rat exon 9-intron 9
probe in experiment 2.  A 4- and 7-fold increase relative to Time 0 in G6PD mRNA was




Sample glucose and insulin fatty acid
1 519.0 608.8
2 764.1 642.3
Values in table are expressed as RLU X 10-3/µg protein.
B
-galactosidase mRNA
Experiment glucose and insulin fatty acid
1 30.5  4          28.9  4
2 82.7  8          77.4  11
3 82.5  2          75.9  1
CAT mRNA
Experiment glucose and insulin fatty acid
1           75.4  23          69.3  18
2         382.5  5        413.5  22
3           25.9  1          30.9  2
Values in table represent the average X 10-4/15µg RNA  SE of 3 samples per treatment.
C
Endogenous G6PD mRNA
Experiment Fold-increase due to
glucose and insulin





Values in table represent the average of 3 samples per treatment.
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Figure 5.  The cytomegalovirus (CMV) promoter is not regulated by arachidonic acid.  A)
-galactosidase activity measurements:  Hepatocytes were isolated as described.  4 h after
plating, the cells were transiently transfected with pCMV by liposome-mediated uptake.
The cells were incubated for 14 h in the presence of the DNA/liposome complexes.  After
the 14 h incubation, 27 mM glucose and 0.1 µM insulin with or without 250 µM
arachidonic acid was added to the cells and incubated an additional 72 h.  The medium
was changed every 24 h.  After 72 h with the indicated treatments, cell extracts were
prepared from 2 plates per treatment. 	The results are expressed as relative light units
(RLU) X 10 -3 per µg protein and 2 samples per treatment are shown.  B)  -galactosidase
mRNA measurements:  Hepatocytes were isolated and cotransfected with pCMV and
pRSV-CAT in experiments 1 and 2.  In experiment 3, hepatocytes were cotransfected
with pCMV-GL3-gal and pRSV-CAT.  Treatments were added as described above for the
activity measurements.  Total RNA was isolated from 3 plates (60 mm) per treatment
after 24 h with the indicated treatments.  The RNA (15 µg) was analyzed using a
ribonuclease protection assay with probes for -galactosidase and CAT.  Quantitation
was done using ImageQuaNT analysis.  The actual numbers from ImageQuaNT are
shown.  For ease of reporting, all values were multiplied by 10-4.  Values represent the
average  SE of 3 samples per treatment.  C)  To ensure that the population of cells from
these experiments were responsive to fatty acids, endogenous G6PD mRNA was
measured in experiments 1 and 2 using a ribonuclease protection assay with the exon 13
rat probe (experiment 1) the exon 9-intron 9 rat probe (experiment 2).  In experiment 3,
endogenous G6PD mRNA was measured using Northern analysis.  Results are expressed
as the calculated fold-increase due to glucose and insulin and the % inhibition due to fatty
acid and are the average of 3 samples per experiment.
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experiments 1 and 2).  A 70% and 42% inhibition of G6PD mRNA due to the addition of
arachidonic acid was observed in experiments 1 and 2, respectively.  Thus the cells used
in these two experiments were responding to the indicated treatments and the lack of
regulation of pCMV was because it is not regulated by these treatments and not a
reagent or cell viability problem.
As an additional control to ensure that the sequences of the parent vector used for
the pcDNA construct were not mediating this regulation, the pGL3-Basic vector with the
CMV promoter and -galactosidase gene in place of the G6PD gene (pCMV-GL3-Gal)
was transfected in hepatocytes along with pRSV-CAT.  Expression of the -galactosidase
or RSV-CAT transgenes was not regulated with any of the experimental treatments (Fig.
5B, experiment 3).  Endogenous G6PD regulation was also observed in this population of
cells and is shown in Fig. 5C, experiment 3.  Thus, any regulation observed with
thetransgenes would be mediated via a G6PD specific sequence, not the promoter or
vector sequences.
pcDNA transgene mRNA is found in the same nuclear fractions as the endogenous G6PD
mRNA
During the first 48-72 h after transient transfection, transcription of the foreign
DNA occurs in the nucleus but the transfected plasmid may not be integrated into the
genome.  In the case of the endogenous gene, we hypothesize that dietary fat blocks the
association of the newly transcribed G6PD RNA with the nuclear matrix or increases its
degradation on the matrix during processing.  Thus, we determined if the transgene
mRNAs also follow this same intranuclear processing pathway.  If negative results are
obtained in the transfection experiments, this could be because a cis-acting element is not
present or because transient transfection does not allow the transgene to follow the same
processing pathway as for the endogenous gene.  If the latter is the case, then stable
transfection which results in the integration of the transgene into the genome of the host
cell would be necessary for these studies.
To test this, we fractionated hepatocytes following transfection into five fractions:
cytoplasmic, nuclear membrane, DNase soluble, salt soluble and the nuclear matrix
fractions.  We examined the endogenous gene using probes to detect both precursor and
mature forms of the endogenous gene.  Pre-mRNA should be in the nuclear matrix
fraction and after processing, the mature mRNA should be found in the nuclear
membrane and cytoplasmic fractions.  G6PD specific RNA was found in all fractions
except the DNase soluble fraction (Fig. 6A).  When analyzed on a denaturing agarose gel
stained
105
                A





































































































Exon 13 mouse 
(transgene)
Exon 13 rat 
(endogenous gene)
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Figure 6.  The pcDNA transgene colocalizes with the endogenous gene in subcellular
fractions.  A)  Hepatocytes were isolated as described and cultured in the presence of
glucose (27 mM) and insulin (0.1 µM) for 24 h.  Cellular fractionation was performed as
described in Materials and Methods.  RNA (20 µg) from each cellular fraction was
analyzed using a ribonuclease protection assay with two G6PD specific probes, exon 9-
intron 9 and intron 3-exon 4.  B)  Hepatocytes were isolated as in Part A).  After the 4 h
attachment period, the cells were washed and transfected with the pcDNA construct.
Fourteen hours after transfection, the DNA/liposome complexes were removed and
glucose (27 mM), insulin (0.1 µM) and a Matrigel overlay (0.3 mg/ml) were added to the
cells.  The cells were incubated for an additional 24 h in the presence of this treatment.
Cellular fractionation was performed from 80 plates and 20 µg of RNA from each
fraction was analyzed using a ribonuclease protection assay with the exon 13 mouse
probe to detect transgene expression and the exon 13 rat probe to detect endogenous
G6PD expression.  Digested and undigested lanes represent the probes hybridized with 20
µg of yeast RNA with or without RNase digestion, respectively.
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with ethidium bromide (EtBr), the RNA from the DNase soluble fraction was degraded
(data not shown) which explains the lack of G6PD signal in this fraction.  The RNA from
the salt soluble fraction was also somewhat degraded.  Consistent with the hypothesized
role of the nuclear matrix, pre-mRNA for G6PD was detected in this fraction (Fig. 6A).
Onlymature mRNA was found in the cytoplasmic, nuclear membrane and salt soluble
fractions.  Thus, the distribution of G6PD mRNAs in the rat hepatocytes is similar to the
distribution observed in the intact mouse.
Fractionation was next done with hepatocytes transfected with the pcDNA
construct and with a single treatment, glucose and insulin.  The amount of G6PD
transgene sequences in each fraction was compared to that of the endogenous gene using
a ribonuclease protection assay and the exon 13 probe (Fig. 6B).  Expression of mRNA
from the transgene as measured by the mouse exon 13 probe was found in the same
nuclear fractions as the endogenous gene.  Again, no G6PD transgene or endogenous
gene signal was observed in the DNase soluble fraction, consistent with degradation of
this sample as observed on an EtBr stained denaturing agarose gel (data not shown).  In
this experiment, the cytoplasmic, nuclear membrane and nuclear matrix all showed
similar amounts of G6PD mRNA levels.  The salt soluble fraction had 40% less mRNA
than the other fractions in both the transgene and the endogenous gene.  These probes do
not distinguish between the unspliced and spliced species of RNAs.  The additional band
observed beneath the rat exon 13 band is due to the single base pair difference in the
mouse exon 13 probe which results in an extra cut in the hybrid during the RNase
digestion.  Thus, RNA produced from transiently transfected DNA is in the same
fractions as the endogenous gene and therefore transient transfection is an ideal way to
rapidly screen the functional activity of the chimeric constructs.
G6PD mature sequences contain a fatty acid response element
The specificity of this unique nuclear posttranscriptional regulatory mechanism
for G6PD must be achieved via cis-acting elements within the pre-mRNA for G6PD.  In
order to test for the presence of cis-acting elements in the G6PD gene, it was necessary to
design chimeric constructs to look at portions of the gene.  The primary transcript is 18 kb
in length, therefore, we chose to start with the cDNA which is 2.3 kb and a 1 kb fragment
of the 3’-UTR.  These regions have been shown to contain regulatory elements for other
genes.
A representative ribonuclease protection assay is shown in Fig. 7A.  There was




Transfected mouse exon 13 mRNA/CAT mRNA
Time 0 Glucose and Insulin Fatty acid
Expt 1 0.60  0.1 1.20  0.1 0.66  0.1
Expt 2 0.86  0.1 2.07* 1.07  0.2
(2.31,1.84)
Results in table represent average of 3 samples per treatment  SE.
* Represents average of 2 samples per treatment.  Value from each sample is shown in






























Figure 7.  The mature G6PD mRNA sequences contain a putative fatty acid response
element.  A)  Hepatocytes were isolated as described.  Four hours after plating, the cells
were cotransfected with the pcDNA test construct and pRSV-CAT as a control for
transfection efficiency.  Fourteen hours later, the medium was changed to one containing
glucose (27 mM) and insulin (0.1 µM) with or without arachidonic acid (250 µM) with a
0.3 mg/ml Matrigel overlay.  Total RNA was isolated from each individual plate (3
plates/treatment) after 24 h with the indicated treatments or before any treatments were
added (Time 0).  Each RNA sample (20 µg) was hybridized with 3 probes in the same
tube:  mouse exon 13, rat exon 13 and CAT.  Analysis was done using a ribonuclease
protection assay.  A representative blot is shown.  U= Undigested control; D= Digested
control; M= Marker.  Part (B) shows the quantitative results of 2 separate experiments.
Results are expressed as mouse exon 13 mRNA divided by CAT mRNA for 2 separate
experiments and are the average of 3 samples per treatment  SE except for the glucose
and insulin value in experiment 2 with only two samples, the separate values are provided
in parenthesis.  The average fold-increase due to glucose and insulin is only calculated for
the endogenous gene.  The % inhibition due fatty acid are shown for both the transgene
and the endogenous gene as an average of 2 separate experiments.
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CAT probe versus the endogenous gene as measured by the rat exon 13 probe.  In
subsequent experiments, we have confirmed that the band for endogenous G6PD is
indeed the correct band (data not shown).  CAT mRNA expression remained relatively
constant in all samples with all treatments.  Expression of the G6PD transgene showed
the same regulatory pattern as endogenous gene expression.  Fig. 7B shows the
quantitative data of two separate experiments expressed as mouse exon 13 mRNA
divided by CAT mRNA in the top panel.  The calculated percent inhibition due to
arachidonic acid was 45 and 46% for experiments 1 and 2, respectively.  The fold-
increase due to glucose and insulin cannot be calculated for the transgene because
expression of the transgene varies with time independent of treatment in transient
transfection.  Expression of the endogenous gene was increased 2.5- and 6.5-fold in
experiments 1 and 2, respectively.  A 44 and 55% inhibition of this stimulation was
observed due to arachidonic acid.  RNA from nontransfected cells was also analyzed from
the same hepatocyte populations.  Based on Northern analysis, endogenous G6PD mRNA
expression was increased an average of 6-fold due to incubation with glucose and insulin.
This stimulation was inhibited by an average of 47% due to the addition of arachidonic
acid to the cells.  Thus, transfection did not alter the responsiveness to fatty acids.  The
similar inhibition in both the transgene and the endogenous gene due to arachidonic acid
suggests that the transgene contains a fatty acid regulatory sequence.  Thus, we have
localized a PUFA regulatory region within 2.3 kb of the G6PD mature sequence.
Next, hepatocytes were isolated and transfected with each of the three 3’-UTR
constructs and pRSV-CAT.  The results of three independent experiments showed no
consistent pattern of regulation of any of the transgenes (data not shown).  Regulation of
the endogenous gene was observed within the same experiments.  Thus, the cells were
responding to fatty acids but we could not make any conclusions regarding the role of the
3’-UTR.
Discussion
Posttranscriptional regulation at a nuclear level by dietary polyunsaturated fat has
not been previously described for other genes and thus represents a very novel mechanism
of regulation.  The ultimate question then leading to the design of these experiments is
how does regulation of this gene occur without changes in the half-life of the pre-mRNA?
Identification of these processes is of interest not only to understanding the intracellular
actions of fatty acids but also to understanding novel mechanisms of gene regulation.
Our hypothesis is that the specificity of the nuclear posttranscriptional effect must
be achieved via a cis-acting regulatory element within the G6PD precursor mRNA
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sequence to which a trans-acting protein may bind.  We did a series of experiments to
localize a PUFA regulated cis-acting element that may be responsible for this unique
form of regulation by fat.  The mouse G6PD cDNA transgene demonstrated the same
regulation as the endogenous rat G6PD gene, thus a fatty acid regulatory element resides
in the 2.3 kb region.  To determine the validity of our results, we first determined that the
CMV promoter, which was used to drive the expression of all constructs, and the parent
vector sequences were not regulated by arachidonic acid.  Second, we demonstrated that
the pcDNA transgene is found in the same nuclear compartments as the endogenous gene,
indicating the RNA from the transgene used a common processing pathway.  Third, we
cotransfected with RSV-CAT to ensure that changes in transgene expression were not due
to differences in transfection efficiency.  Not only was regulation of pcDNA still
observed after correction for transfection efficiency but there was little difference in the
transfection efficiency between plates.  Fourth, inhibition of the endogenous gene
expression by arachidonic acid was identical to that observed with the transgene.  This
was observed in both transfected and nontransfected hepatocytes within the same
experiment.  Thus, we have localized a PUFA response element to 2.3 kb of the mature
G6PD sequences.
It is unclear whether the carbohydrate stimulation achieved by refeeding a starved
animal and the fatty acid inhibition achieved by consumption of a high-fat diet will
follow the same molecular mechanism.  Both dietary regimens are regulated at a nuclear
posttranscriptional step (6); however, the cis-acting elements and trans-acting proteins
may be different in each case.  We were unable to calculate the fold-increase due to
glucose and insulin for the pcDNA transgene due to the experimental design.  Time 0
RNA was isolated at 18 h into the culture whereas the RNA from samples treated with
glucose and insulin was isolated at 42 h into the culture.  Expression of the transgenes
vary with time independent of treatment (data not shown).  Insulin response elements
could be localized by comparing hepatocytes treated with glucose alone versus insulin
alone.  The search for glucose response elements would be more difficult since most cell
culture media contain small amounts of glucose and the cells do not survive in a complete
absence of glucose.  Although this has not been directly tested, polyunsaturated fat does
not appear to induce the synthesis of another protein because the effect of dietary fat and
arachidonic acid is very rapid (4.5 h in the intact animal and 2 h in cells in culture).  In
addition, when hepatocytes are incubated with glucose alone (no insulin) we do not
observe inhibition by arachidonic acid.  Thus, polyunsaturated fatty acids may interfere
with insulin signaling which would suggest that the glucose and insulin response
elements would overlap with the PUFA response element in the G6PD pre-mRNA.
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There are several possibilities for how this regulation may occur.  The first
possibility is that regulation of G6PD expression occurs very early in the processing
pathway, either on entry of the pre-mRNA into the pathway or very early in the
processing reactions.  Pre-mRNA which enters the processing pathway, as may be the
case with a low-fat diet (in the presence of glucose and insulin), is stable; pre-mRNA that
does not enter the pathway, as may be the case with a high-fat diet (in the presence of
arachidonic acid) is degraded in the nucleus by RNases.  This mechanism could involve
the binding of a trans-acting protein to a cis-acting element within the pre-mRNA.  On
binding, this protein could target the RNA for processing perhaps by association with the
nuclear matrix, the location of processing of many transcripts (11-14).  A protein may be
induced during high-carbohydrate, low-fat feeding (in the presence of glucose and
insulin) which allows attachment to the nuclear matrix to occur.  Conversely, in animals
fed a high-fat diet (in the presence of arachidonic acid), the amount of this protein may be
reduced resulting in either a block in entry of pre-mRNA into the processing pathway or
enhanced degradation during processing.  Another possibility is that fat may alter the
conformation of the putative regulatory protein so that it cannot bind to the regulatory
sequence.  Preliminary data from our laboratory supports this model.  In this regard, in
livers of mice fed a high-carbohydrate, low-fat diet, G6PD pre-mRNA copurifies with the
nuclear matrix and more processed mRNA accumulates on the nuclear matrix.  Starvation
or high-fat feeding results in less pre-mRNA in the matrix and a block in accumulation of
more processed RNA (Amir-Ahmady and Salati, unpublished).  Fig. 8 summarizes this
model for regulation of G6PD by polyunsaturated fat.
There are two other genes which are thought to be regulated through enhanced
stability of the nuclear pre-mRNA, perhaps through processing on the nuclear matrix.
Regulation of fibronectin by transformation with H-ras (30) or treatment with
dexamethasone (31) occurs by changes in accumulation of nuclear precursor mRNA in
the absence of changes in the rate of transcription, polyadenylation, or alternative splicing
of the fibronectin transcript.  Tissue-specific expression as well as regulation by retanoic
acid of the liver/bone/kidney alkaline phosphatase gene also involves small changes in
the amount of nuclear precursor mRNA without changes in transcriptional activity (32).
Enhanced stability of these nuclear RNAs is the hypothesized mechanism however these
conclusions are not based on measurements of changes in pre-mRNA half-life.  Exact
identification of the cis-acting sequences and trans-acting factors have not yet been
elucidated.
The second possibility is that regulation of G6PD occurs through a pathway
similar to that described for nonsense codon containing mRNAs.  Nuclear mRNAs can be
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Figure 8.  Proposed model for G6PD regulation by polyunsaturated fatty acids.  Nuclear
posttranscriptional regulation of G6PD occurs early in processing by differential
accumulation of the pre-mRNA in the processing pathway.  This mechanism may involve
the binding of a trans-acting factor to a cis-acting element within the pre-mRNA.  Perhaps
a protein is induced during high-carbohydrate, low-fat feeding which allows attachment
to the nuclear matrix and facilitates the movement of the pre-mRNA through the nuclear
processing reactions thus protecting it from degradation.  In the animal fed a high-fat diet,
the activity or amount of this protein may be decreased and thus association with the
nuclear matrix would not occur.  Alternatively, binding to the nuclear matrix may occur
but the pre-mRNA may not enter any further into the processing pathway.  Pre-mRNA
not associated with the nuclear matrix would then be susceptible to degradation by
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destabilized by the presence of nonsense codons, also called premature termination
codons, as has been reported for the triosephosphate isomerase (TPI) gene (33).  The
nonsense mutation in TPI is caused by a genetic mutation, not regulation by diet or
hormones (34).  RNA produced with the nonsense codon undergoes rapid decay either
within the nucleus or during transport through the nuclear pore (15).  Nonsense-mediated
decay requires the presence of at least one intron after the premature termination codon
which implicates nuclear splicing as an effector of this pathway (35).  According to the
accepted model for nonsense-mediated decay, all exon-exon junctions within a multi-
intron gene may be “marked” with a remnant of the splicing machinery.  This “mark”
must be positioned at least 50 nt downstream but less than 550 nt downstream of the
nonsense codon in order to be recognized by the proposed nuclear scanner (36).  This
scanner within the nucleus or at the nuclear pore recognizes and degrades mRNAs
containing premature stop codons.  This may be a component of the translation
termination complex or a completely distinct mechanism.
At first glance it seems that we do not have the structural elements required for
this pathway since the PUFA regulation is observed with the pcDNA construct which
does not contain an intron sequence and second there are no nonsense codons in the
G6PD coding region.  It is possible that G6PD is regulated by a variation of this
nonsense-mediated decay pathway.  For example, it is possible that a splicing factor such
as a serine-arginine (SR) protein may bind to the putative regulatory sequence that we
have localized in an exon under all dietary conditions.  SR proteins recognize sequences
within the exons of mRNA (14).  In the presence of glucose and insulin, an additional
regulatory protein may be induced which binds to this SR protein to mediate the entry of
the mRNA into the processing pathway.  In the presence of arachidonic acid, this protein-
protein interaction may not occur.  The presence of the SR protein alone on the G6PD
exon may “mark” the message for decay by an unknown mechanism.  A similar scanning
mechanism may be responsible for decay, similar to that described for nonsense-
containing messages (15).  One possibility for the putative trans-acting protein is an SR
kinase which may phosphorylate the SR protein to allow the pre-mRNA to enter the
processing pathway.  It will be necessary to distinguish whether glucose and insulin
induces a stimulatory protein or induces the decay of an inhibitory protein.  If the later is
the case, then arachidonic acid may block the decay of the inhibitory protein.
To date, polyunsaturated fatty acid response elements have been conclusively
identified in three other genes:  L-PK (37), S14 (38), and SCD1 (39).  G6PD is the fourth
example of a polyunsaturated fatty acid response element.  However, this is the only
element which has been found in the coding sequence.  All others have been found in the
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promoter region of genes and are involved in regulation at a transcriptional level.  It is
possible that there is more than one class of polyunsaturated response element in the
genes that are regulated transcriptionally.  In fact, posttranscriptional mechanisms have
been found to occur coincidentally with transcriptional mechanisms in some genes (8-10).
It is possible that all of the other lipogenic genes possess some components of this
posttranscriptional pathway which would allow more rapid changes in their expression in
response to nutritional stimuli.  This pathway has not been studied with these genes
because of the difficulty of distinguishing between transcriptional and posttranscriptional
mechanisms for changing pre-mRNA accumulation.  G6PD may have adapted this
exclusive posttranscriptional mechanism due to its roles in maintenance of redox state
and cell growth.  In this way, the organism maintains uniform expression of G6PD in all
tissues but can increase expression in certain tissues when the needs for lipogenesis are
great.
Our long term goal is to determine if cis-acting elements identified in the rat
hepatocyte culture model are the same elements used by dietary fat in the intact animal.
These experiments will require transgenic approaches.  The presence of different cis-
acting elements would suggest that PUFA-regulated factors do not have generalized
effects on regulatory pathways, but are rather gene specific.  The trans-acting proteins still
need to be identified to determine if there is a general pathway for all genes.  Most likely
there will be multiple factors involved.  This is the first example of a PUFA-regulatory
region found in a coding region and that is part of an exclusively posttranscriptional
regulatory mechanism.  Future work includes analysis of the deletion constructs to further
localize the response element followed by characterization of an RNA binding protein
that interacts with this region.  An ultimate goal of this laboratory is to trace the signal
transduction pathway within hepatocytes by which fatty acids cause a change in gene
expression.
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APPENDIX
Hepatocyte isolation.  The following is a more detailed procedure for the
isolation of rat hepatocytes.  This is a very intricate procedure and requires precise timing
of certain steps in order to achieve viable cells.  Thus, I will describe all of the steps in
detail from injection of the animal to the end of the purification steps.
Rats used as hepatocyte donors were injected interperitoneally with 250 µl of
Nembutal (50 mg/ml) per 200 g animal immediately before surgery.  It was necessary to
secure the animal to a styrofoam support with autoclave tape and place this support in a
metal tray to collect the perfusion buffer.  The abdominal region was wet with 70%
ethanol to avoid contamination from animal hair; shaving this region was not necessary.
A midline incision was made starting above the pelvis and up to the sternum.  Lateral cuts
were then made so that the skin flaps could be pushed to the side exposing the abdominal
region.  The esophagus was clamped just above the stomach with a hemastat.  A cut was
made above the clamp so that the intestines and the stomach could be pushed to the right
so as to expose the portal vein.  To help expose the abdominal cavity, the barrel from a 30
ml syringe was placed under the back of the animal.  Three pieces of surgical silk
(approximately 6 inches each; Harvard Apparatus Cat # 51-7706) were inserted around
the portal vein.  The silk furthest from the liver was tied very loosely around the vein.  A
16 gauge 1.88 inch catheter (Angiocath Cat # 330017; Central Supply, Ruby Hospital,
WV) was inserted into the vein, over the lower piece of silk.  As the needle was pulled
out of the catheter, blood flowed down the needle, indicating proper insertion.  The
perfusion tubing, which contained the Ca2+-free buffer (500 ml), was attached
immediately.  It was necessary to ensure that no bubbles were present in the tubing and
buffer was allowed to drip from the tubing at a rate of 1-3 ml/min.  Any air entering the
liver through this manner would ruin the cell viability.  The flow rate was increased to 20
ml/min and the inferior vena cava was cut to allow the buffer to flow out.  The point from
pulling out the needle to cutting the inferior vena cava should take a maximum of 5 sec.
The first sign of perfusion is that the liver becomes tan immediately as the blood is
pushed out.  The other surgical silk ties were knotted down, the lower one to cut off blood
supply to the vein, and to tie down the catheter, the upper two to tie the catheter to the
portal vein.  This was followed by cutting through the diaphragm and cutting the superior
vena cava.  The flow rate was increased to 40 ml/min and the ties were double-checked
for tightness.  The point from pulling out the needle to the increase in flow rate to 40
ml/min should take no longer than 1 min to complete.  This perfusion was continued until
350 ml of perfusion buffer was used.  At that time, the collagenase solution (100 ml
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filtered into a 150 ml glass bottle) was released into the perfusion tubing and the Ca2+-
free buffer was stopped.  Collagenase releases the cells from the matrix within a few
minutes; this is easily observed upon visual inspection.  After 100 ml of collagenase
buffer was perfused, the tubing was removed from the catheter.  The liver was then cut
away from the body cavity and transferred to a sterile petri dish.  The cells were combed
away from the intestinal string and the purification steps were begun.
The initial cell suspension after the collagenase digestion contains intact
parenchymal cells, variable nonparenchymal and damaged cells, cell clumps, pieces of
connective tissue and vascular tissue, and subcellular debris.  The purpose of the
purification was to remove all contaminants and end up with intact parenchymal cells.
All purification steps were carried out at 4C.  The cell solution was brought up to 20 ml
with Williams’ E medium [supplemented with 23 mM Hepes, pH 7.4, 26 mM sodium
bicarbonate, penicillin (100 U/ml), streptomycin (100 µg/ml) and gentamicin (50 µg/ml)]
and filtered through 105 µm mesh (Spectra/Mesh) to remove the connective tissue and
cell clumps.  The cells were gassed with 95% O2/5% CO2 for 1 min and centrifuged at 50
X g for 3 min.  The supernatant was removed and the pellet was resuspended in 20 ml of
media.  The cells were gassed and centrifuged again exactly as before.
At this point, the cells were observed under a microscope for viability using
trypan blue exclusion.  When cells are incubated with trypan blue, a non-viable cell has a
blue cytoplasm; a viable cell has a clear cytoplasm.  In a 15 ml tube, 1.2 ml media, 0.15
ml cells and 0.15 ml trypan blue (Gibco-BRL Cat # 15250-061) is added and mixed.  A
few drops of cells are added under the cover slip of a hemacytometer.  The
hemacytometer is placed on the microscope and lined up under a grid of 4 X 4 boxes.
Both live and dead cells are counted in the 4 X 4 area.  Cells from 3 different 4 X 4 areas
should be counted to get a better estimate of the number of cells.  If 100 total cells are in
the 4 X 4 area, this means that there are 10.0 X 106 cells/ml.  The number of dead cells
divided by the number of total cells multiplied by 100 gives the percentage of dead cells.
This number is subtracted from 100 to give the percentage of viable cells.  If cells were
greater than 90% viable based on trypan blue exclusion, 25 ml of the cell solution was
added to 24 ml of a pre-prepared Percoll solution [9:1 mixture of Percoll (Sigma Cat #
P4937) and 10X Hanks Balanced Salt Solution].  This was mixed well by inversion and
centrifuged 50 X g for 10 min.  The supernatant was removed and the cell pellet was
resuspended in 10 ml of media.  The cells were gassed as before and centrifuged at 50 X
g for 2 min.  This step was repeated one time.  The cells were counted using a
hemacytometer and trypan blue exclusion as described above and adjusted to 8 X 106
cells/ml.  0.5 ml of cells at this density were added to each 60 mm plate that was
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preconditioned with 2.5 ml of media containing 5% newborn calf serum (Gibco-BRL Cat
# 26010-074).  The cells were incubated for 4 h in the presence of serum to allow
attachment to the plates.  At this point the media containing serum was removed and
replaced with one without serum.  The remainder of the steps concerning the maintenance
of the cells was determined based on the purpose of the experiment.
pcDNA deletion constructs.  To more precisely locate the fatty acid response
element of the G6PD gene, we have subcloned the pcDNA construct into smaller
fragments.  These fragments were not tested in transfection experiments due to problems
that arose in the cell culture system.  Plasmids containing smaller subsets of the G6PD
cDNA sequence were made by digestion of the pcDNA construct using convenient
restriction enzymes.  Following digestion with HindIII and the indicated enzymes in the
construct name, the desired fragments were gel isolated, filled in with Klenow treatment
to create blunt-ends and religated.  The new constructs were verified by sequencing
through the deletions and by restriction digestion.  The BglII construct was only digested
with BglII and therefore blunt-ends did not need to be created.  These constructs are
shown in Figure 1.
122
Figure 1.  pcDNA deletion constructs.  The full-length pcDNA construct was divided into
smaller fragments using restriction enzyme digestion.  The numbers represent the 13
exons of G6PD.  Four deletion constructs were made:  pcDNA BstEII which contains
exons 3-13, pcDNA BglII which contains exons 6-13, pcDNA PvuII which contains
exons 9-13 and pcDNA SacII which contains exons 12 and 13.  Figure is not drawn to
scale.
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